Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)


1) Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2) Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 3) Department of Surgery, Iwakuni Clinical Center, Iwakuni, Japan, 4) Department of Cancer Prevention and Molecular Genetics, Saitama Prefectural Cancer Center, Saitama, Japan, 5) Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan, 6) Department of Coloproctology, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan, 7) Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, 8) Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan, 9) Department of Surgical Oncology, The Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 10) Division of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Genetic Research, Tokyo, Japan, 11) Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan, 12) Endoscopy Division/Department of Genetic Medicine and Service, National Cancer Center Hospital, Tokyo, Japan, 13) Department of Surgery, Keio University School of Medicine, Tokyo, Japan, 14) Department of Surgery, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan, 15) Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan, 16) Department of Surgery Saitama Medical Center, Jichi Medical University, Saitama, Japan, 17) Department of Oncology Nursing, Faculty of Nursing, Toho University, Tokyo, Japan, 18) Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, 19) Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan, 20) Department of Surgery, Teikyo University, Tokyo, Japan, 21) Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan, 22) Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan, 23) Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, 24) Department of Translational Oncology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan, 25) Colorectal Surgery Division, National Cancer Center Hospital, Tokyo, Japan, 26) Department of Gastroenterology, St. Mary's Hospital, Fukuoka, Japan, 27) Department of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan, 28) Hepatopancreato-Biliary Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 29) Radiation Oncology Department, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 30) Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan, 31) Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan, 32) Department of Surgery, Kyoto University, Kyoto, Japan, 33) Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan, 34) Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 35) Department of Surgery, National Defense Medical College, Saitama, Japan, 36) Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan, 37) Department of Hemodialysis and Surgery, Chemotherapy Research Institute, International University of Health and Welfare, Ichikawa, Japan, 38) Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan, 39) Diagnostic Pathology Center, Shinko Hospital, Kobe, Japan, 40) Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan, 41) Department of Health Administration and Policy, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 42) Department of Surgery, Cancer Center, Aomori Prefectural Central Hospital, Aomori, Japan.

Corresponding author: Hideyuki Ishida, 05hishi@saitama-med.ac.jp
Received: June 26, 2017, Accepted: September 15, 2017
Copyright © 2018 The Japan Society of Coloproctology
This is a translated version. The original version of this manuscript was produced by the Japanese Society for Cancer of the Colon and Rectum [Japanese Society for the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer. 1st ed. Tokyo: KANEHARA & CO., LTD: 95p. Japanese].
Abstract:
Hereditary colorectal cancer accounts for less than 5% of all colorectal cancer cases. Some of the unique characteristics that are commonly encountered in cases of hereditary colorectal cancer include early age at onset, synchronous/metachronous occurrence of the cancer, and association with multiple cancers in other organs, necessitating different management from sporadic colorectal cancer. While the diagnosis of familial adenomatous polyposis might be easy because usually 100 or more adenomas that develop in the colonic mucosa are in this condition, Lynch syndrome, which is the most commonly associated disease with hereditary colorectal cancer, is often missed in daily medical practice because of its relatively poorly defined clinical characteristics. In addition, the disease concept and diagnostic criteria for Lynch syndrome, which was once called hereditary non-polyposis colorectal cancer, have changed over time with continual research, thereby possibly creating confusion in clinical practice. Under these circumstances, the JSCCR Guideline Committee has developed the “JSCCR Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (HCRC),” to allow delivery of appropriate medical care in daily practice to patients with familial adenomatous polyposis, Lynch syndrome, or other related diseases. The JSCCR Guidelines 2016 for HCRC were prepared by consensus reached among members of the JSCCR Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR Guidelines 2016 for HCRC.

Keywords:
hereditary colorectal cancer, guideline, familial adenomatous polyposis, Lynch syndrome

Introduction

1. Guideline objectives

In Japan, the incidence of colorectal cancer has been steadily increasing; it is presently one of the most frequently encountered cancers in clinical practice and a cause for great concern. Most colorectal cancers are thought to be caused by the accumulation of gene mutations in the colonic mucosa or adenomas, the occurrence of which is thought to be influenced by lifestyle, environmental factors, advanced age, etc. (sporadic colorectal cancer). Another type of colorectal cancer, called familial colorectal cancer, which accounts for 20-30% of all colorectal cancer cases, is commonly found among relatives (familial clustering). In less than approximately 5% of colorectal cancer cases, the causative genes have been identified, irrespective of the presence or absence of familial clustering, and these cases are collectively referred to as cases of hereditary colorectal cancer. Early age at onset, synchronous/metachronous occurrence, association with multiple cancers in other organs, etc., are usually seen in cases of hereditary colorectal cancer; therefore, this type of cancer should be managed differently from sporadic colorectal cancer. However, hereditary colorectal cancer is still not well-recognized by general clinicians.

Familial adenomatous polyposis and Lynch syndrome have high incidence rates in cases of hereditary colorectal cancer. While detection of familial adenomatous polyposis might be facilitated by its common occurrence in 100 or more adenomas of the colonic mucosa, Lynch syndrome, which is the most commonly associated disease with hereditary colorectal cancer, is often missed in daily medical practice owing to its relatively poorly defined clinical characteristics. In addition, Lynch syndrome was once called hereditary non-polyposis colorectal cancer (HNPPC), and its disease concept and diagnostic criteria have changed with continuing research, thereby possibly creating confusion in clinical practice.

Under these circumstances, the “JSCCR Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer” (hereafter referred to as the JSCCR Guidelines 2016 for HCRC), intended for doctors and medical personnel engaged in providing medical care to patients with familial adenomatous polyposis, Lynch syndrome, and other related diseases, have been developed for the following purposes:

1) To deepen the understanding of the concept of heredi-
Clinical guidelines for hereditary colorectal cancer

(2) To provide guidance on management strategies, including diagnosis and surveillance, for hereditary colorectal cancer

(3) To emphasize the importance of the need to consider the psychosocial burden caused by hereditary diseases in patients and their families (relatives) as well as their need for support

(4) To enhance mutual understanding between healthcare professionals and patients by making these guidelines available to the public.

2. How to use the JSCCR Guidelines 2016 for HCRC

The JSCCR Guidelines 2016 for HCRC can be used as a tool for the treatment of hereditary colorectal cancer under actual clinical practice settings. More specifically, they can be referred to for the diagnosis/treatment/surveillance of individual patients or for obtaining informed consent for genetic testing and optimal treatment selection etc. from patients and their families. The JSCCR is responsible for the statements in the JSCCR Guidelines 2016 for HCRC. However, the personnel directly in charge of treatment, and not the JSCCR or the Guideline Committee, must take responsibility for treatment outcomes.


1) Circumstances of the development of JSCCR Guidelines 2016 for HCRC

The JSCCR planned to develop “the JSCCR Guidelines for the Clinical Practice of Hereditary Colorectal Cancer” as a project of the Familial Colorectal Cancer Committee, and published the “JSCCR Guidelines 2012 for HCRC” in July 2012. Subsequently, several new findings and clinical practice guidelines, particularly regarding Lynch syndrome, were published from overseas. In addition, the Familial Colorectal Cancer Committee itself analyzed data from “A Retrospective Multicenter Study of Familial Adenomatous Polyposis” and “Registration and Genetic Analysis of HNPCC -Secondary Study-,” which were studies conducted by the JSCCR, and obtained new findings. Under these circumstances, the clinical genetics departments have been established, mainly in specialized institutions, and hereditary tumors have increasingly become an issue of social concern in Japan. Based on the above, revision of the guidelines published in 2012 was initiated in 2015. A draft revision was prepared after many discussions and submitted to the Guideline Evaluation Committee in May 2016. In addition, a public hearing was held in the 85th annual meeting of the JSCCR in July 2016, and subsequently, the revised points were published on the website of the JSCCR to collect opinions from the public. Further revisions were made by reference to these opinions, and finally the “JSCCR Guidelines 2016 for HCRC” was published in November 2016.

We attempted to develop the JSCCR Guidelines 2016 for HCRC in accordance with the concept of evidence-based medicine. However, the incidence of hereditary colorectal cancer is relatively low, and it is not easy to design high-evidence-level studies. In view of this difficulty in obtaining sufficient evidence, the guidelines have been developed by consensus reached among members of the JSCCR, based on information obtained from literature searches, and considering the medical health insurance system and actual clinical practice situation in Japan. In addition, members of the Japanese Society for Familial Tumors also participated in the Guideline Development Committee.

2) Principles behind Guideline development

The JSCCR Guidelines 2016 for HCRC presents evidence for each management strategy to enable clearer understanding of the management strategies, including the diagnosis, treatment, and surveillance of hereditary colorectal cancer; however, the technical aspects of each treatment method have not been discussed.

3) Extraction and evaluation of evidence

The method adopted for guideline development was in accordance with the concept of EBM. However, because hereditary colorectal cancer is a relatively rare disease and it is difficult to conduct randomized controlled trials, the evidence levels have not been shown.

4. Description method

Familial adenomatous polyposis and Lynch syndrome, which have relatively high incidence rates among cases of hereditary colorectal cancer, were selected, and (1) the disease concept, (2) diagnosis, (3) treatment, (4) postoperative surveillance, (5) management of patients and their families, etc., were briefly described for each disease. Next, contents suitable for inclusion in clinical questions (CQs) were selected and discussed by the Guideline Development Committee.

5. Method for describing the recommendations

Each recommendation in response to a CQ is accompanied, as much as possible, by classifications of the evidence and recommendation categories, based on consensus reached among members of the Guideline Development Committee. In determining the recommendation categories, in addition to an evaluation of the validity of the source of evidence for each recommendation, a comprehensive investigation of the validity and clinical applicability of each recommendation was performed, by ascertaining that the diagnosis and treatment methods are based on clear scientific evidence, are the best and safest available, are minimally invasive, and are in line with those used in actual clinical practice in Japan.

Classification of the recommendation categories are as follows:

- Category A: unanimous recommendation by the Guide-
Table 1. Changes in the Mortality Rates of Various Cancers and Other Conditions Over Time in Patients with Familial Adenomatous Polyposis.

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Up to 1980 (n=268)</th>
<th>1981-1990 (n=166)</th>
<th>1990-2003 (n=71)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal cancer</td>
<td>80.2%</td>
<td>77.7%</td>
<td>60.6%</td>
</tr>
<tr>
<td>Desmoid tumor</td>
<td>3.0%</td>
<td>4.8%</td>
<td>9.9%</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>3.0%</td>
<td>2.4%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Duodenal/periampullary cancer</td>
<td>1.8%</td>
<td>2.4%</td>
<td>5.6%</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>0%</td>
<td>0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Small bowel cancer</td>
<td>1.2%</td>
<td>1.2%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Myocardial infarction/heat failure</td>
<td>1.8%</td>
<td>2.4%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.4%</td>
<td>1.2%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>0.9%</td>
<td>2.4%</td>
<td>5.6%</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>0.7%</td>
<td>0.6%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Uterine cancer</td>
<td>0.5%</td>
<td>0.6%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Gastric ulcer</td>
<td>0.2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Esophageal cancer</td>
<td>0.2%</td>
<td>0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Gallbladder cancer</td>
<td>0.2%</td>
<td>0.6%</td>
<td>0%</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>0.2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>0.2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>0%</td>
<td>0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Accident</td>
<td>2.1%</td>
<td>2.4%</td>
<td>0%</td>
</tr>
<tr>
<td>Other diseases</td>
<td>1.6%</td>
<td>1.2%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Unknown</td>
<td>0.2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Suicide</td>
<td>0.2%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>All cases</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Age at the time of death (average ± SD) 41.9 ± 11.9 44.0 ± 13.9 46.0 ± 15.6

Modifications with ref. 2)

6. Method of literature search

The PubMed and Ichushi-Web databases were selected for the literature search, and the English and Japanese literature was systematically searched in both databases for the period from the earliest possible date to August 2015. The exhaustive literature search was performed for the broad category, namely, “familial adenomatous polyposis,” to obtain articles on familial adenomatous polyposis, and for the broad categories, “Lynch syndrome,” “hereditary non-polyposis colorectal cancer,” “microsatellite instability,” and “mismatch repair,” to obtain articles on Lynch syndrome; manual searching was added as required. The full texts of the articles selected from 25,941 extracted documents with abstracts (familial adenomatous polyposis: 1,049 Japanese articles and 7,897 English articles; Lynch syndrome: 1,050 Japanese articles and 16,045 English articles) were critically examined. In addition, important articles published from September 2015 onward were also adopted after full examination.

7. Revision

In cooperation with the Japanese Society for Familial Tumors, the JSCCR Guideline Committee and Familial Colorectal Cancer Committee, as the central organizations, shall aim to revise the JSCCR Guidelines 2016 for HCRC in 4 years, in principle.

8. Publication

The JSCCR Guidelines 2016 for HCRC will be published as a pamphlet and will be made available to the public on the website of the JSCCR, etc., so that the guidelines can be widely used under clinical settings throughout Japan.
Chapter 1: Familial Adenomatous Polyposis

1. Outline

- Familial adenomatous polyposis (FAP) is a hereditary autosomal dominant disease caused by germline mutations in the Adenomatosis Polyposis Coli (APC) gene, and it is characterized by the development of multiple colorectal adenomas (Side Memo 1: Method for describing genomic alterations, germline and somatic mutations; Appendix: II. Method for describing genomic variants).
- If not treated, almost all FAP patients develop colorectal cancer.
- FAP patients can develop not only colorectal cancer, but also various other associated tumorous and non-tumorous lesions in the gastrointestinal tract and other organs.

[Clinical features]

- Some FAP patients have been reported to develop colorectal cancer while still in their teenage years while approximately 50% of the patients develop colorectal cancer by their 40s. If left untreated, almost all patients develop colorectal cancer by around 60 years of age. (Attachment I).
- The most common cause of death in FAP patients is colorectal cancer, which accounted for approximately 80% of all causes of death in FAP patients until the 1980’s; however, the proportion has been decreasing toward approximately 60% from the 1990’s (Table 1).
- Among the main extracolonic manifestations (Table 2), duodenal cancer and desmoid tumor are major causes of death in addition to colorectal cancer in FAP patients.

[Causative gene]

- APC gene on chromosome 5 (5q22.2)

[Mode of inheritance]

- Autosomal dominant inheritance

[Mechanisms of tumorigenesis] (Figure 1A, 1B)

- In addition to a germline mutation in one of the two alleles of the APC gene, an acquired second-hit somatic alteration, such as a deletion in the other allele of the APC gene in the epithelial cells of the large intestine (loss of heterozygosity [LOH]), is thought to be the cause of aberrant crypt foci (ACF) (Side Memo 1: chromosomal instability, loss of heterozygosity). (Side Memo 1: aberrant crypt foci).
- Dysfunction of the APC protein causes accumulation and nuclear translocation of cytoplasmic β-catenin; then, nuclear β-catenin forms a complex with TCF4, which promotes transcription.
- The mechanism via which APC protein malfunction causes chromosomal instability (CIN) remains unknown; however, in the presence of APC protein malfunction, somatic alterations such as LOH tend to occur in oncogenesis-related genes. In the development of colorectal cancer from ACF via the adenoma-carcinoma sequence, additional mutations are thought to occur in carcinogenesis-related genes such as KRAS and TP53 genes (multi-hit theory or multi-stage model).

[Incidence]

- The estimated incidence of FAP in the overall population is 1:20,000 to 1:10,000 in Western countries, and 1:17,400 in Japan. Less than 1% of all patients with colorectal cancer are estimated to have FAP. According to a JSCCR multicenter study, 0.24% of all colorectal cancer patients have FAP.

Table 2. Major Neoplastic Lesions Associated with Familial Adenomatous Polyposis.

<table>
<thead>
<tr>
<th>Lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundic gland polypsis</td>
</tr>
<tr>
<td>Gastric adenoma</td>
</tr>
<tr>
<td>Duodenal adenoma</td>
</tr>
<tr>
<td>Periampullary adenoma</td>
</tr>
<tr>
<td>JEJunal/ileal adenoma</td>
</tr>
<tr>
<td>Desmoid tumor</td>
</tr>
<tr>
<td>Skull osteoma/jaw osteoma/unerupted teeth/extra teeth (supernumerary teeth)</td>
</tr>
<tr>
<td>Epidermoid cyst</td>
</tr>
<tr>
<td>Thyroid cancer</td>
</tr>
<tr>
<td>Congenital hypertrophy of the retinal pigment epithelium</td>
</tr>
<tr>
<td>Hepatoblastoma</td>
</tr>
<tr>
<td>Adrenal tumor</td>
</tr>
<tr>
<td>Brain tumor</td>
</tr>
</tbody>
</table>

*: possibility of malignant transformation
Changes in genomic sequences have often been represented by terms such as “mutation” and “polymorphism.” However, because the use of these terms may be perceived differently by different individuals, thus causing confusion, the use of terms such as “sequence variant,” “alteration,” and “allelic variant” is recommended. These terms represent the presence of changes compared to reference sequences, but do not indicate any causal relationship with diseases. In addition, the expression “pathogenic” may be used, only after carefully considering what situations it can be used in, and other expressions such as “affect function” may be used in the future.

- Germline and somatic mutations
  - Gene mutations transmitted through the sperm or ovum are called germline mutations. Since these mutations are present in the fertilized ovum, all cells of the body have these mutations. On the other hand, new gene mutations in non-germ cells constituting the body, or non-germline mutations, are called somatic mutations.
  - APC gene mutations in FAP
    - In the tumors of patients with FAP, germline and somatic mutations of the APC gene result in the production of a truncated APC protein, which is thought to be an inactive form of the protein.
  - Chromosomal instability (CIN)
    - CIN represents abnormalities in the number or structure (deletion, duplication, translocation, etc.) of chromosomes seen in cancer and other cells, and it is thought to cause tumorigenesis.
  - Loss of heterozygosity (LOH)
    - Heterozygosity indicates the presence of different base sequences in a homologous region of a pair of genetic information inherited from the parents. In the case of FAP, pathogenic mutations are present only in one of the two alleles of the APC gene, and the other allele is normal (wild type) in normal cells. This state is called heterozygosity. However, loss of the wild-type APC allele by deletion, referred to as LOH, occurs during the process of oncogenesis.
    - Aberrant crypt foci (ACF)
    - ACF cannot be distinguished from normal mucosa by normal endoscopic observation, and can only be confirmed by magnifying endoscopy as clusters of abnormal crypts showing strong staining with methylene blue. Some ACF are thought to be precursor lesions of adenomas and/or carcinomas.

2. Diagnosis

1) Flow of diagnosis (Figure 2)
   - FAP may be diagnosed clinically and/or genetically.
     - [Clinical diagnosis]
       - If either of the following criteria (1) or (2) is satisfied, a diagnosis of FAP is made.
         - (1) Detection of approximately 100 or more adenomas in the large intestine, irrespective of the presence/absence of a family history of FAP.
         - (2) Detection of less than 100 adenomas in the presence of a family history of FAP.
     - [Genetic diagnosis]
       - If a pathogenic germline mutation is present in the APC gene, a diagnosis of FAP is made.
       - There are exceptional pathologies other than FAP that are characterized by the presence of approximately 100 or more adenomas in the large intestine (MUTYH-associated polyposis, an autosomal recessive disease). Therefore, a family history consistent with autosomal dominant inheritance is a useful clue for the diagnosis of FAP.
Irrespective of the number of colorectal adenomas, the presence of characteristic extracolonic manifestations is a useful clue for the diagnosis of FAP. In 20-40% of patients clinically diagnosed with FAP, no mutations are detected in the APC gene<sup>8,9</sup>. (CQ1)

If a patient wishes to undergo genetic testing for his/her own treatment or for the diagnosis in his/her relatives, or if attenuated FAP (AFAP) has to be differentiated from MUTYH-associated polyposis and polymerase proofreading-associated polyposis (PPAP), genetic testing of the APC gene is considered. This testing can be performed in testing companies (not covered by the national health insurance program) (Side Memo 2: genetic testing) (CQ1).

2) Classification according to the density of the colorectal adenomas

- FAP is sometimes classified as profuse FAP, sparse FAP, and attenuated FAP, according to the density of the adenomas. Profuse FAP and sparse FAP are sometimes collectively called typical (classical) FAP.
- Density of adenomas has been reported to be associated with the site of the germline mutation in the APC gene and with the risk of development of colorectal cancer.
- Profuse FAP: Normal mucosa cannot be visualized macroscopically because of the profusion of adenomas (Figure 3) However, often, adenoma density is found to differ even among regions of the large intestine.
- Sparse FAP: Multiple adenomas can be observed on a background of normal mucosa. The number of adenomas is approximately ≥10 (Figure 4).
- Attenuated FAP (AFAP)<sup>koc</sup>: The number of adenomas is approximately ≥10 and <100 (CQ2).
- In cases of profuse FAP, a germline mutation is often
seen between codons 1250 to 1464 (in particular, codon 1309) in the APC gene\(^{10,11}\). In AFAP, the germline mutation is often seen in the alternative splicing region (in which an exon is skipped during transcription because of the mutation), or in the 5’ or 3’ region of the APC gene\(^ {12}\).

According to the JSCCR multicenter study, the age at diagnosis of adenomas and the age at diagnosis of cancer in the colorectum are often lower among patients with profuse FAP than in those with other types of FAP. It has been reported that approximately half of the patients with profuse, sparse, and attenuated types develop colorectal cancer by age 40, 47, and 55 years, respectively.

Side Memo 2
- Difference between the profuse and sparse types

FAP is sometimes classified according to the number of colorectal adenomas into the profuse (>1,000 or 2,000 adenomas) and sparse (100-1,000 or 2,000 adenomas) types. Many reports classify these types of FAP as typical FAP, and FAP associated with a smaller number (10-99) of adenomas as AFAP. Strict differentiation between the profuse and sparse types is of little clinical significance.

3) FAP-associated lesions
- FAP is often associated with extracolonic tumorous and/or non-tumorous lesions.
- Presence of tumorous lesions, such as fundic gland polyposis (Figure 5), gastric adenoma (Figure 6) (CQ10), duodenal adenoma (Figure 7) (CQ11), ampullary adenoma (CQ12), desmoid tumor (Figure 8) (CQ14), subcutaneous soft tissue tumor/osteoma, and dental abnormalities (Figure 9) serve as useful clues for the diagnosis of FAP (Side Memo 3: Gardner syndrome).
- FAP patients without Helicobacter pylori (H. pylori) infection often tend to have fundic gland polyposis, as compared to those with H. pylori infection\(^ {13}\). Surveillance for fundic gland polyposis is required in FAP patients, because of the risk of malignant transformation of fundic gland polyps in these patients.
- FAP patients often develop depressed-type or protruded-type gastric adenomas (Figure 6).
Congenital hypertrophy of the retinal pigment epithelium (Figure 10), a non-tumorous lesion, is detectable before the development of colorectal adenomas in FAP patients, and it is a helpful clue for diagnosis (Side Memo 3: Congenital hypertrophy of the retinal pigment epithelium).

FAP patients may also develop other tumorous lesions, including desmoid tumor, thyroid cancer, adrenal tumor, hepatoblastoma, and brain tumor (Side Memo 3: Turcot syndrome).

Side Memo 3

Gardner syndrome
Colorectal polyposis associated with subcutaneous soft tissue tumors, osteomas, dental abnormalities, desmoid tumors, etc., was once called Gardner syndrome, and was regarded as different from FAP, but subsequently, like FAP, this syndrome was also found to be caused by germline mutations in the APC gene. At present, the term Gardner syndrome is usually not used.

Congenital hypertrophy of the retinal pigment epithelium (CHRPE)
CHRPE is a discontinuous flat pigmented lesion of the retina without clinical symptoms, which does not require any treatment. It does not affect visual acuity and does not show malignant transformation. Because approximately 80% of FAP patients have CHRPE, and because it can be detected at birth, it is a helpful clue for the diagnosis of FAP in children.

Turcot syndrome (type 2)
Colorectal polyposis associated with brain tumor (mainly cerebellar medulloblastoma), and with a germline mutation in the APC gene is called Turcot syndrome, type 2 (see Lynch syndrome for Turcot syndrome, type 1).

4) Diseases and pathological conditions that should be differentiated from FAP

APC mosaicism:
If somatic mutations in the APC gene were to occur during the process of tumorigenesis, a mosaic of cells with and without the mutations in the APC gene would result. If this abnormality were to occur in cells that differentiate into mucosal cells of the large intestine, multiple colorectal adenomas would develop, like in FAP. It has been reported that APC mosaicism occurs in 1.6-4% of FAP patients with identified mutations in the APC gene and 11-20% of FAP pa-
Patients with a negative family history\textsuperscript{14-15}. Clinically, this condition is managed as FAP. In addition, mutations in the \textit{APC} gene, if present in some germ cells (sex mosaicism), may be passed on to the next generation.

\textit{MUTYH-associated polyposis (MAP)}:

MAP is a hereditary autosomal recessive disease caused by biallelic germline mutation of the \textit{MUTYH} gene, which is one of the base excision repair genes\textsuperscript{16}. MAP is characterized by the presence of about 10-100 adenomas in the large intestine, although some patients could have as many as 100-1,000 adenomas\textsuperscript{17}. The incidence of germline mutations in the \textit{MUTYH} gene is unknown among Japanese colorectal cancer patients. The penetrance of colorectal cancer (proportion of individuals who develop colorectal cancer among those with gene mutations) is 43-100\% in individuals aged up to 60 years\textsuperscript{18}. Some MAP patients have been reported to develop a variety of lesions like those found in FAP. In Japan, there are few case reports of MAP, and this disease remains poorly understood. Treatment for MAP is like that for AFAP.

\textit{Polymerase proofreading-associated polyposis (PPAP)}:

PPAP is a hereditary autosomal dominant disease caused by pathogenic germline mutations in the \textit{POLE} or \textit{POLD1} gene, both of which repair errors in DNA replication (proofreading function)\textsuperscript{19}. Many patients have a few dozen colorectal adenomas, while some patients have been reported to have no adenomas. As extracolonic manifestations, duodenal adenomas/cancers and brain tumors have been reported to develop in patients with PPAP carrying mutation of the \textit{POLE} gene\textsuperscript{20} and endometrial cancers, breast cancers, and brain tumors have been reported to develop in patients with PPAP carrying mutations of the \textit{POLD1} gene\textsuperscript{21}. Tumors of the large intestine (colorectal adenomas and cancers) in PPAP are histologically indistinguishable from these tumors in sporadic cases. Therefore, genetic testing is necessary for a definitive diagnosis.

3. Treatment

1) Treatment of colorectal adenomas

- Proctocolectomy or colectomy prior to the development of colorectal cancer is a reliable prophylactic treatment.
The main surgical procedures adopted are as follows (Figure 11, Table 3):

1. Total proctocolectomy + permanent ileostomy (TPC)
2. Restorative proctocolectomy + ileal pouch-anal anastomosis (IPAA)
3. Total colectomy + ileorectal anastomosis (IRA)
   - At present, IPAA is thought to be the standard surgical procedure and it is commonly performed in FAP patients (CQ3,CQ4).
   - In general, it is recommended that patients undergo prophylactic surgery when they are in their 20’s. (CQ5)
   - Nomenclature of the surgical procedures
   - In Western countries, ileal pouch anal anastomosis with mucosectomy (IAA) and ileal pouch anal canal anastomosis (IACA) are often collectively called ileal pouch-anal anastomosis (IPAA), without discrimination between them. In addition, IAA is sometimes called hand-sewn IPAA, and IACA is sometimes called stapled IPAA. The height of the anastomosis (length of the residual rectum) is not clearly defined for ileorectal anastomosis (IRA). Total proctocolectomy + permanent ileostomy is often called total proctocolectomy (TPC).
   - In recent years, laparoscopic surgery has been increasingly used for prophylactic proctocolectomy (colectomy). (CQ6)
   - In cases where desmoid tumors are found in the mesentery during prophylactic surgery, IPAA is generally not recommended, owing to the risk of recurrence or enlargement of desmoid tumors and technical problems, but it may be acceptable under certain conditions. (CQ3)
   - Total proctocolectomy for FAP may reduce fertility in females. (CQ7)
   - Drug therapy with non-steroidal anti-inflammatory drugs (NSAIDs) has been attempted; however, its usefulness is unclear. (CQ8)

2) Treatment of colorectal cancer

- In FAP patients with locally advanced colorectal cancer, standard treatment for locally advanced colorectal cancer should be undertaken. If curative resection of the colorectal cancer can be expected, the surgical procedure should be selected according to the condition of the FAP.
- In FAP patients with locally advanced colorectal cancer, the surgical procedure should be determined after a comprehensive consideration of the stage and site of the colorectal cancer. If curative resection of the colorectal cancer can be expected, total proctocolectomy or total colectomy with dissection of the regional lymph nodes is an option; on the other hand, if the colorectal cancer cannot be expected to be curatively resected, a surgical procedure like that for sporadic colorectal cancer should be selected.
- Chemotherapy similar to that used for patients with sporadic colorectal cancer should be used for colorectal cancer associated with FAP.
- Even after total proctocolectomy or total colectomy, chemotherapy selection can be guided by the recommendations in the “JSCCR Guidelines 2016 for the Treatment of Colorectal Cancer.”
   - If metastatic lesions can be expected to be curatively resected, treatment similar to that for metastases from sporadic colorectal cancer should be used.

3) Examinations for extracolonic manifestations before proctocolectomy (colectomy)

- It is desirable to carry out extensive examinations to check for extracolonic manifestations prior to colorectal resection, irrespective of the presence or absence of associated locally advanced colorectal cancer, although there is little evidence of its usefulness.
- It is recommended to check for the presence of gastrointestinal lesions, including ampullary and desmoid tumors prior to colectomy.
- Examinations for other tumorous lesions can be performed during the surveillance after proctocolectomy (colectomy).
- Presence/absence of adenomas and cancers of the stomach and duodenum, including of the ampulla of Vater, should be checked by upper gastrointestinal endoscopy.
- Presence/absence of desmoid tumors should be checked for by palpation, CT, and/or MRI.
- Ultrasonography to check for thyroid cancer need not necessarily be performed before colectomy, but it must be incorporated into the postoperative surveillance plan, especially in female patients.
- In general, small-bowel follow-through and small-bowel endoscopy (capsule endoscopy) are not performed before proctocolectomy (colectomy) except when there are symptoms/findings (including preoperative diagnostic imaging findings) raising the suspicion of intestinal lesions.
- Because adrenal tumors develop at a low frequency, and hepatoblastomas and brain tumors develop commonly only until 2 to 3 years of age and up to adolescence, respectively, preoperative examinations for these tumorous lesions are, in general, not required.

4. Postoperative surveillance

1) Surveillance specific to proctocolectomy (colectomy)

- If there is any residual colorectal mucosa after prophylactic proctocolectomy (colectomy), regular colonoscopic examination is required, in view of the possibility of new colorectal cancer development.
- In FAP patients undergoing surgery for colorectal cancer, postoperative surveillance similar to that in sporadic colorectal cancer patients should be planned/ performed.
- Long-term surveillance to monitor the development of cancer in the remaining rectum is required after IRA (CQ9).
- Usually 2 to 3 cm of rectal mucosa is left behind after stapled IPAA, and a small amount of rectal mucosa may also be left behind after hand-sewn IPAA. Therefore, long-
also been reported to develop after surgery for ulcerative colitis stapled IPAA and after hand-sewn IPAA. (CQ32) 
Baseline upper gastrointestinal endoscopy starting at the time of colectomy or at 20-25 years old, whichever is earlier. Thereafter, upper gastrointestinal endoscopy repeated regularly depending on the severity. (CQ32) 
Abdominal palpation every year 
After colectomy, abdominal and pelvic CT or MRI every 3 years for patients with a family history of desmoid tumors 
Radiologic examination every year 
Data to support any recommendation are lacking. Simultaneously with radiological examinations (CT/MRI) for desmoid tumors

Modification with ref. 33)
Clinical questions

CQ1: Under what circumstances is genetic testing required for the diagnosis and treatment of FAP?

Recommendation category: B

Genetic testing of the APC gene is required in the following cases.

1. When the results of genetic testing are planned to be used as reference for treatment selection or surveillance in patients clinically diagnosed with FAP.

2. When, in a pedigree in which a pathogenic germline mutation of the APC gene has been detected, relatives of the patient wish to undergo genetic testing.

3. When the results of genetic testing are to be used for the diagnosis of AFAP or in the differential diagnosis of MAP and PPAP.

1. Genetic testing in patients clinically diagnosed as having FAP

FAP is often diagnosed clinically, even in the absence of a family history. However, a relationship between the site of the pathogenic germline mutation in the APC gene and the number of colorectal adenomas, other associated lesions, etc., has been reported, and genetic testing is sometimes useful for treatment selection or surveillance.

2. Genetic testing in the relatives of a patient with a known pathogenic germline mutation in the APC gene
Genetic testing allows FAP to be diagnosed in the relatives (e.g., children) of a patient with a known pathogenic germline mutation of the \textit{APC} gene.

3. Diagnosis of AFAP or differential diagnosis of \textit{MUTYH}-associated polyposis

Although AFAP can often be clinically diagnosed based on the number of polyps in the colorectum (less than 100) and a family history consistent with autosomal dominant inheritance, extracolonic manifestations, etc., identification of a pathogenic germline mutation in the \textit{APC} gene is useful for a definitive diagnosis. If only the patient or only the sibling(s) of the patient among the family members have less than 100 colorectal adenomas, the patient or the siblings may have \textit{MUTYH}-associated polyposis, and genetic testing of the \textit{APC} gene, followed by, or simultaneously with, genetic testing of the \textit{MUTYH} gene is useful in the differential diagnosis between the two conditions. \textit{MUTYH}-associated polyposis is inherited in an autosomal recessive manner, and it is important to clarify which gene is mutated, considering risk assessment, surveillance, etc., in relatives.

No pathogenic germline mutations of the \textit{APC} gene are identified in some patients who have been clinically diagnosed with FAP. According to a report from Western countries\(^3\), pathogenic germline mutations of the \textit{APC} gene are identified by usual testing methods in approximately 60% of patients with classical (typical) FAP, and pathogenic \textit{APC} germline mutations and biallelic mutations of the \textit{MUTYH} gene are identified in 10% and 7% of patients respectively, with 20 to 99 colorectal adenomas, and in 5% and 4%, of patients respectively, with 10 to 19 colorectal adenomas. Possible reasons for the failure to detect pathogenic germline mutations of the \textit{APC} gene include: (1) difficulty in the detection of \textit{APC} gene alterations by the analysis method used, (2) presence of unknown causative genes for adenomatous polyposis, (3) \textit{APC} mosaicism, (4) MAP, and (5) PPAP.

The “Guidelines for Genetic Tests and Diagnosis in Medical Practice” of the Japanese Association of Medical Sciences\(^38\) and the guidelines of genetics-related societies should be observed, in principle, in genetic testing. Genetic testing under these circumstances is not covered by the national health insurance program in Japan; however, genetic testing of the \textit{APC} gene can be outsourced to testing companies. Approximately 2 to 3 mL of whole blood is required for the genetic testing.

**CQ2: What are the points that should be kept in mind while treating attenuated FAP (AFAP)?**

Recommendation category: C

Total colectomy + ileorectal anastomosis (IRA) and long-term surveillance by colonoscopy should be considered in patients with AFAP.

It is difficult to confidently diagnose AFAP based only on the number of colorectal adenomas (less than 100); however, a family history of FAP and fundic gland polyposis, duodenal adenoma, exostosis, desmoid tumor, congenital hypertrophy of the retinal epithelium (CHRPE), etc., that may be associated with FAP or AFAP serve as helpful clues for diagnosis\(^9\,10\,40\).

If the above-mentioned characteristics are unclear, differentiation from \textit{MUTYH}-associated polyposis and polymerase-proofreading-associated polyposis is difficult, necessitating genetic testing for definitive diagnosis.

In AFAP, pathogenic germline mutations of the \textit{APC} gene are often found in the 5’ or 3’ region, alternative splicing region (in which an exon is skipped during transcription due to the mutation), etc. of the \textit{APC} gene\(^41\), while no mutations may be identified in many cases.

The mean age of colorectal cancer development is higher in AFAP patients than in typical FAP patients. Burt et al.\(^41\) reported that the mean age at the diagnosis of AFAP was 41 years and that the number of colorectal adenomas was variable, with a mean of 25 (0-470) in 120 individuals from 2 families surveyed. The mean age at onset of colorectal cancer was 58 (21-81) years, and 75% of the patients had cancer of the right colon. The cumulative incidence of colorectal cancer up to 80 years of age (69%) was lower than that in typical FAP patients (almost 100%). According to the JSCCR multicenter study, the mean age at onset of colorectal cancer was 50 years in AFAP patients, and half of the patients developed colorectal cancer by 55 years of age, which was later in life than that in typical FAP patients. Therefore, in AFAP patients without rectal cancer, IRA\(^12\) and long-term follow-up by colonoscopy\(^40\) are valid options.

**CQ3: What are the points that should be considered when selecting a surgical procedure for FAP patients?**

Recommendation category: B

Total proctocolectomy + ileal pouch-anal anastomosis (IPAA) is the standard surgical procedure. Total colectomy + ileorectal anastomosis (IRA) is also a valid option in patients with sparse FAP and those with a small number of rectal adenomas.

IPAA is the standard surgical procedure for typical FAP\(^23\) (Figure 13). An ileal pouch is generally constructed in a J-shape\(^25\). IPAA is largely divided into hand-sewn IPAA, in which the rectal mucosa is dissected from the dentate line and an ileal pouch is anastomosed manually to the dentate line, and stapled IPAA, in which stapling Anastomosis of the surgical anal canal and ileal pouch is performed. The former procedure leaves only a small amount of rectal mucosa, but requires a greater level of skill in the operator. The JSCCR multicenter study revealed that recently, in Japan, laparoscopic surgery has been used in more than 70% of cases and that hand-sewn IPAA has been selected in an increasing proportion of cases\(^26\). (CQ6)

IRA is recommended for AFAP cases. IRA is considered
not only in AFAP patients, but also in sparse-type FAP patients who have less than 20 rectal adenomas with a maximum diameter of less than 10 mm, young females who wish to become pregnant, and children/adolescents before school age/employment, etc. A metaanalysis comparing IPAA and IRA revealed that IRA was better in the improvement of the stool frequency, defecation at night and pad use than IPAA; however, IPAA was better than IRA in the improvement of fecal urgency. The incidence of postoperative complications (within 30 days) was significantly higher after IPAA (23.4% vs. 11.6%). There were no differences in the postoperative sexual function, dietary restriction, long-term complications, or incidence of developing desmoid tumors between IPAA and IRA. It has been reported that the incidence of postoperative complications after IPAA is reduced with increased surgical skill level of the surgical team.

In patients with mesenteric desmoid tumors, it is often difficult to perform IPAA, and IRA is usually selected. However, there is an opinion that if the bottom of the ileal pouch reaches the pelvic floor, IPAA can also be performed.

Total proctocolectomy + permanent ileostomy, which was used before the spread of anus-preserving surgery, is rarely performed as prophylactic surgical treatment. According to the JSCCR multicenter study, this procedure was performed in approximately only 3% of all cases including colorectal cancer. Total proctocolectomy + permanent ileostomy should be reserved for patients with locally advanced lower rectal cancer, those with poor anal function, and those in whom the ileal pouch does not reach the pelvic floor, etc.

In patients with colorectal cancer, the choice of surgical procedure should be based on a comprehensive consideration of the degree of progression and site of the cancer (See Chapter I; 3. Treatment; 2) Treatment of colorectal cancer).

**CQ4: Is temporary ileostomy required in cases undergoing IPAA for FAP?**

Recommendation category: None

Temporary ileostomy is not required in all cases, but its need should be determined on a case-by-case basis considering its advantages and disadvantages.

A recent meta-analysis of patients treated by IPAA revealed that patients in whom temporary ileostomy was performed had a lower incidence of anastomotic leakage, but higher incidence of anastomotic stricture and bowel obstruction. It has been reported that temporary ileostomy can be avoided under the following circumstances: in patients with (1) stapling anastomosis, (2) no anastomotic tension, (3) complete anastomosis, (4) sufficient hemostasis, (5) no anastomotic air leak, and (6) no evidence of malnutrition, infection, anemia or regular steroid use. Anastomotic leakage after IPAA may cause an important long-term complication, namely, pouch failure. Anal dysfunction and poor expansion of the ileal pouch have been reported as possible causes of pouch failure. From these points of view, it is considered that temporary ileostomy may be useful in the prevention of anastomotic leakage and pelvic abscess, or suppress the degree of these adverse events as much as possible after IPAA. However, it should be kept in mind that the above studies...
included both patients with ulcerative colitis and those with FAP, the latter accounting only for a small proportion of the subjects.

Studies of IPAA conducted on only FAP patients have reported that temporary ileostomy is performed in most patients, except some of those undergoing stapled IPAA. In a study on the usefulness of temporary ileostomy in FAP patients aged less than 20 years old, patients in whom temporary ileostomy was not performed showed favorable long-term defecation control, but had significantly higher incidence of anastomotic leakage within 30 days of surgery (17.2% vs. 0%, \(P = 0.002\)) and a higher reoperation rate (20.7% vs. 4.6%, \(P = 0.02\)). However, most subjects included in this study underwent stapled IPAA, and further studies of temporary ileostomy in patients undergoing hand-sewn IPAA are required.

The JSCCR multicenter study showed that temporary ileostomy was performed in 55% of patients who had undergone IPAA.

A systematic review of the closure of temporary ileostomy revealed that closure was safe, but that 16.5% of all subjects had postoperative complications, including bowel obstruction in 7.6% (reoperation in 2.9% of all cases), anastomotic leakage in 2.0%, wound infection in 4.0%, and late complications such as incisional hernia in 1.9% and bowel obstruction in 9.4%.

Considering the above, temporary ileostomy can be avoided in selected FAP patients undergoing IPAA, but it is not easy to clearly determine its indications. Therefore, it is practical to determine the need for temporary ileostomy on a case-by-case basis, taking into consideration its advantages and disadvantages.

**CQ5: At what age is prophylactic proctocolectomy (colectomy) recommended to prevent colorectal cancer in FAP patients?**

Recommendation category: B

In general, the surgery is performed when the patients are in their 20's; however, the decision should be made after comprehensively considering the patient sex, density of colorectal adenomas, presence/absence of malignant transformation of the adenomas, associated lesions, the patient’s social background, etc.

The most important considerations in deciding the timing for prophylactic (procto)colectomy in FAP patients are: (1) cumulative prevalence of colorectal cancer; (2) density of the adenomas; (3) size and morphology of the adenomas; (4) age at death, age at cancer onset, and presence/absence of desmoid tumors in members of the pedigree; (5) germ-line mutation site in the \(APC\) gene; (6) educational, work, and other environments of the patient; (7) fertility and presence/absence of male sexual dysfunction after IPAA; (8) presence/absence of gastrointestinal symptoms, such as diarrhea, abdominal pain and melena; and (9) the histopathological findings of the tumor. Considering the prevalence of colorectal cancer, it is recommended that some classic FAP patients should undergo surgery while in their teens, and that most FAP patients should undergo surgery while they are in their 20's.

According to the JSCCR multicenter study, the cumulative incidence of developing colorectal cancer (excluding intramucosal cancer) was approximately 1% in patients aged 20 years and increased to 9.6% and 21.4% in AFAP and classic FAP patients aged 30 years, respectively. Thus, the incidence is higher in classic FAP patients (Attachments: I. Familial adenomatous polyposis; Attachment Table 3: Cumulative incidence of developing colorectal cancer and duodenal adenoma).

**CQ6: Is laparoscopic surgery useful for FAP?**

Recommendation category: C

The decision to undertake laparoscopic surgery for FAP should be made after a full informed consent is obtained from the patient, according to the skill of the operator at the institution.

Recently, laparoscopic surgery has been used in an increasing proportion of patients undergoing IPAA or IRA (IPAA: 23-53%; IRA: 58-62%). According to previously published reports, laparoscopic surgery takes a longer time, but there are no differences between laparoscopic and open surgery in the incidence of postoperative complications, mortality, reoperation rate or readmission rate; furthermore, the laparoscopic approach yields better esthetic outcomes with less intraoperative bleeding. In addition, laparoscopic surgery was also reported to be associated with a lower incidence of postoperative bowel obstruction, due to lower risk of occurrence of intra-abdominal adhesions and a lower incidence of postoperative fertility impairment in females. According to the JSCCR multicenter study conducted recently, laparoscopic surgery has been used in more than 70% of cases, and among the subjects of this study, the laparoscopic approach had been used in 74 out of 171 (43%) patients undergoing IPAA and 52 out of 85 (61%) patients undergoing IRA.

Concerning the short-term outcomes of laparoscopic surgery, the operation time is long; however, safety is secured. The decision to undertake laparoscopic surgery for FAP should be made after a full informed consent is obtained from the patient, according to the skill of the operating surgeon at the institution.

**CQ7: Does IPAA have adverse effects on fertility, pregnancy, and delivery in female patients with FAP?**

Recommendation category: None

IPAA may be associated with postoperative reduction in fertility, but has little adverse effect on pregnancy or deliv-
ery.

A study involving 58 female Danish patients with FAP showed that their fertility rate was 90%, equivalent to that in the general population. A study involving 162 female European patients with FAP demonstrated that the fertility rate in FAP patients who had not undergone any surgery was equivalent to that in the general population. In addition, while the fertility rate of FAP patients who had undergone IRA was also equivalent to that in the general population, the fertility ratio was reduced to 0.46 in FAP patients who had undergone IPAA. On the other hand, a study involving 138 Dutch patients with FAP reported that fertility was not related to the surgical procedure, but to the age at first surgery.

The reduction in fertility after IPAA is thought to be caused by postoperative adhesions. Oresland et al. reported that hysterosalpingography after total proctocolectomy revealed adhesion of the fallopian tube to the pelvic wall in 48% of the cases, unilateral obstruction of the fallopian tube in 43% and bilateral obstruction of the fallopian tubes in 10% of the cases.

A study in which both patients with FAP and those with ulcerative colitis were included, reported that the fertility was significantly higher after laparoscopic IPAA than after IPAA via open surgery. However, there have been no prospective studies including only FAP patients.

Studies including both patients with FAP and those with ulcerative colitis have reported that pregnancy and transvaginal delivery are safe after IPAA. However, the possibility of anal sphincter muscle damage and nerve damage of the pelvic floor muscles after perineal incision must be considered during transvaginal delivery after IPAA.

CQ8: Is there any effective pharmacotherapy for the adenomas in FAP patients?

Recommendation category: C

NSAIDs have been attempted for colorectal adenomas and duodenal adenomas. Although many studies have reported that NSAIDs reduced polyp number, it is unclear whether they are useful in suppressing the development of new adenomas.

Many studies have evaluated the efficacy of sulindac, one of the NSAIDs, for the control of colorectal adenomas in FAP patients. Treatment with sulindac (150-300 mg/day) for 6 weeks to 98 months reduced the number of colorectal adenomas, or the number of rectal adenomas after total colectomy, by 50% or more, whereas 2-year treatment with 150-300 mg/day of sulindac failed to suppress the development of new adenomas.

High-dose (800 mg/day) treatment with celecoxib, one of the selective cyclooxygenase-2 (Cox-2) inhibitors, for 6 months reduced the number of colorectal adenomas by 28% in FAP patients. Celecoxib should be administered at a high dose for a long period of time for suppressing the development of colorectal adenomas in FAP patients. Rofecoxib, another of the selective Cox-2 inhibitors, was also reported to reduce the number of rectal adenomas by approximately 7% after total colectomy. However, because long-term treatment with rofecoxib resulted in a high incidence of cardiovascular adverse events, its use for the prevention or treatment of adenomas is not recommended.

So far, no useful pharmacotherapy to suppress the development of new colorectal or duodenal adenomas has been reported.

CQ9: How should the risk of rectal cancer development be managed after total colectomy + ileorectal anastomosis (IRA)?

Recommendation category: C

Long-term surveillance for the development of cancer in the remaining rectum is necessary.

Long-term follow-up after IRA has revealed that 24-43% of patients develop cancer in the remaining rectum. During a 20-year period after IRA, the rectum had to be resected in 10% of patients with AFAP, 39% of patients with sparse FAP, and 61% of patients with diffuse FAP.

With advances in surgical techniques, IPAA has been used in an increasing proportion of cases, and the use of IPAA in patients with a greater number of risk factors for rectal cancer has reduced the proportion of patients undergoing proctectomy after IRA from 40 to 13%, and has also reduced the cumulative incidence of cancer development in the remaining rectum after IRA.

CQ10: How should gastric lesions be managed in FAP patients?

Recommendation category: C

FAP patients in East Asia have higher risk of gastric cancer than the general population, necessitating long-term endoscopic surveillance.

Approximately 50% of FAP patients develop multiple protrusive polyps in the fundus to the body (fundic gland polyposis). Foveolar-type adenomas (according to the WHO classification) and pyloric gland adenomas are known to develop in the background of fundic gland polyposis, and although rare, development of invasive cancer has also been reported. Particularly, large polyp clusters, with some showing dysplastic or malignant changes, indicate endoscopic resection. Gastrectomy should not be performed for fundic gland polyposis. Solitary or sporadic, depressed- or elevated-type adenomas develop in the antrum. From the above, adenomas measuring 1 cm or more in diameter, as well as sporadic adenomas not associated with FAP, are relative indicators of endoscopic resection, considering the risk of malignant transformation. While the incidence of gastric cancer in FAP patients has been reported to be equivalent to that in...
Figure 14. Histology of FAP-associated duodenal adenomas. A: Low-grade adenoma: The tumor glands are rather uniform and the adenomatous epithelial cells show basally oriented, elongated nuclei. B: Intramucosal carcinoma: Tumor glands show significant irregularity, nuclear stratification, and occasional prominent nucleoli. Note that high-grade dysplasia in the Spigelman classification includes non-invasive intramucosal carcinoma in the Japanese classification. C: Tubular adenoma: This lesion shows a relatively regular tubular architecture. D: Tubulo-villus adenoma: This lesion partially exhibits villous architecture, composed of fibrovascular cores lined by dysplastic epithelium.

the general population in Western countries, it has been reported to be 3-7 times higher in FAP patients than in the general population in East Asia. It is desirable to perform upper gastrointestinal endoscopy once a year (or simultaneously with surveillance for duodenal adenoma surveillance).

CQ11: How should duodenal adenomas (excluding those of the ampulla) be managed in FAP patients?

Recommendation category: C

No consensus has been reached on the treatment or surveillance for duodenal adenomas, but the Spigelman classification can be referred to for optimal treatment and surveillance.

After excluding colorectal cancer, which accounts for death in the majority (61-69%) of FAP patients, duodenal cancer (including ampullary cancer) ranks as the second most common cause of death after desmoid tumors, and accounts for death in approximately 3% of FAP patients. The relative risk of duodenal cancer in FAP patients as compared with that in the general population is 250-330. The cumulative incidence of duodenal cancer by 57 years of age is estimated to be approximately 4.5%. Duodenal adenomas are seen in 30-90% of FAP patients, and the prevalence of adenomas increases after 40 years of age, eventually reaching 90%. Duodenal adenomas grow extremely slowly; however, regular endoscopic surveillance/treatment is necessary. The ISCCR multicenter study found that the cumulative incidence of duodenal adenomas by the age of 50 years was 39.2%, and significantly higher in classic FAP patients than in AFAP patients (42.5% vs. 23.5%). There exists a clinicopathological classification of duodenal adenomas, called the Spigelman classification. In the Spigelman classification, the number and maximum diameter of duodenal adenomas are assessed by endoscopy, and biopsy is used to evaluate the histology and severity of dysplasia. Over time, some modifications have been introduced to this classification (modified Spigelman classification).

Direct-view endoscopy and side-view endoscopy are used to diagnose duodenal adenomas. A study of 37 Dutch patients with FAP showed that the use of narrow-band imaging increased the number of duodenal adenomas detected, but did not affect the results of classification according to Spigelman classification.
Figure 15. Classification of duodenal adenomas by the modified Spigelman classification.

Endoscopic treatments of duodenal adenomas include snare resection, electrocautery, and argon plasma coagulation. Endoscopic electrocautery should be used for adenomas classified as Spigelman stage I/II. Endoscopic or transduodenal resection is not sufficient for patients with many adenomas. It was reported that endoscopic complete resection of adenomas classified as Spigelman stage II/III was associated with a high incidence of complications and a recurrence rate of 50-100%. To date, no clinical trials have been conducted for comparing endoscopic treatment and follow-up of duodenal lesions in FAP patients.

No consensus has been reached on the interval of testing, but it is recommended that testing be performed every 4 to 5 years for cases with stage 0, every 2 to 5 years for cases with stage I, every 2 to 3 years for cases with stage II, and every 6 months to 2 years for cases with stage III duodenal adenomas. Assessment of the indication for surgery or half-yearly to yearly surveillance by a specialist is recommended for patients with stage IV high-grade adenomas, severe adenomatosis, etc. Pancreaticeduodenectomy (PD), pylorus-preserving pancreaticeduodenectomy (PPPD), or pancreas-sparing duodenectomy (PSD) should be considered for patients with stage IV adenomas, because malignant transformation occurs in 7-36% of cases.

Among surgical procedures, PD or PPPD is generally selected, and it was reported that PSD was performed in 13 Danish patients with FAP between 1999 and 2010. Six (46%) of these patients developed postoperative complications, and of these, 3 had anastomotic leakage, but recovered with conservative treatment. According to a report from the Netherlands, 43 out of 1,066 FAP patients underwent duodenectomy (PSD was performed in 22 of these), and PSD has been the first-line surgical procedure for prophylactic duodenectomy since 1999. However, in Japan, PSD is performed in only some hospitals for FAP patients. Management of duodenal adenomas according to the modified Spigelman classification is shown in Figure 16.

Side Memo 5

Changes in the evaluation methods for the Spigelman classification

The Spigelman classification is a staging system for duodenal adenomas associated with FAP that was proposed in 1989. The polyp number, maximal diameter, histology and severity of dysplasia are assessed on a scale ranging from 1 to 3, and the total score is used to determine the disease stage. In the Vienna classification of 2000, the grading of the severity of dysplasia was changed from 3 levels, that is, mild, moderate, and severe, to 2 levels, namely, low-grade and high-grades, and a modified classification was proposed, in which 1 and 3 points are given to the low and high grades, respectively. Recently, the National Comprehensive Cancer Network (NCCN) Guidelines (Genetic/Familial High-Risk Assessment: Colorectal V.2.2015) proposed a classification that was a simpler form of the Spigelman classification, or the modified Spigelman classification. This classification consists of stages 0 (no adenomas), I (1 to 4 tubular adenomas measuring 1-4 mm in diameter), II (5-19 tubular adenomas measuring 5-9 mm in diameter), III (20 or more adenomatous lesions measuring 1 cm or more in diameter), and IV (dense or high-grade adenomas). No prospective studies of the validity of surveillance or treatment based on these staging systems have been conducted, and this issue needs to be addressed in the future.
**CQ12: How should ampullary tumors (adenomas/cancers) be managed in FAP patients?**

Recommendation category: C

Endoscopic or surgical treatment should be selected for ampullary tumors according to the clinical condition and symptoms.

Approximately 50% of FAP patients develop ampullary tumors\(^9,99\). Some AFAP patients also develop ampullary tumors\(^99\). The relative risk of ampullary cancer in FAP patients as compared to that in the general population was reported to be 123.7\(^91\). Endoscopic ampullectomy or transduodenal ampullectomy\(^101,102\) is indicated for tumors localized to the papilla. The former has often been adopted, with recent advances in colonoscopic treatment techniques.

Electrocautery of periampullary lesions (within 2 cm of the papilla), including those of the papilla, has been reported to be safe and effective\(^103\), while it has also been suggested that aggressive treatment is not recommended, because the lesions were found to remain benign over long-term observation for more than 10 years\(^106\). Ma et al.\(^108\) retrospectively investigated the data of 26 FAP patients who underwent endoscopic ampullectomy in the United States between 1990 and 2010. Complications in these patients included pancreatitis (19.2%), abdominal pain (7.6%), and bleeding (3.8%). Of the 24 patients who could be followed up, 14 (58.3%) had local recurrence, and the authors called attention to this problem. Gluck et al.\(^106\) reported that endoscopic follow-up of 80 FAP patients for an average of 7.2 years revealed ampullary tumors in 38 patients (47.5%), of whom 10 had advanced adenomas (tumor diameter 10 mm or more, villous type, high-grade dysplasia), and that endoscopic ultrasonography (EUS) is important for their diagnosis. In addition, 15 underwent endoscopic ampullectomy, of which 2 eventually underwent surgery for recurrent lesions. Regarding surgery, if there is a periampullary lesion that is difficult to treat endoscopically, pancreas-sparing duodenectomy (PSD)\(^107\) may be selected and if any evidence of malignant change is noted, pancreaticoduodenectomy (PD), pylorus-preserving pancreaticoduodenectomy (PPPD), etc., should be selected.

**CQ13: How should jejunal/ileal tumors be managed in FAP patients?**

Recommendation category: C

Small-bowel endoscopy and capsule endoscopy have been attempted, but no consensus has been reached on the examination or treatment of jejunal/ileal tumors in FAP patients.

Jejunal/ileal adenomas develop in 60-75% of FAP patients\(^108-111\). A study using capsule endoscopy showed that patients with duodenal adenomas also tend to have jejunal/ileal adenomas\(^109,112\). Most of these adenomas measure 10 mm or less in diameter\(^111,113,114\). Studies on relatively large numbers of patients have shown that the number of adenomas tends to be higher in the jejunum and lower in the ileum\(^109,114\). In principle, because jejunal/ileal cancer develops rarely\(^115\), endoscopic resection is not indicated for jejunal adenomas. However, how jejunal/ileal adenomas should be examined...
and treated remains to be established, and this issue needs to be addressed in the future.\(^{136}\)

**CQ14: What are the management strategies that should be used for desmoid tumors in FAP patients?**

Recommendation category: C

No consensus has been reached concerning the treatment of desmoid tumors in FAP patients. Pharmacotherapy, surgery, conservative treatment (follow-up), etc., could be selected according to the site and severity of the tumors.

Management strategy for desmoid tumors should be selected taking into consideration the characteristics of the desmoid tumors, types of treatment available, tumor stage, etc.

1. Characteristics

Desmoid tumor is a type of fibroma, which does not metatasis, but tends to show invasive growth. Desmoid tumors are seen in 8-20% of FAP patients,\(^{44,43,117,118}\) intra-abdominal desmoid tumors accounting for 70% of all cases.\(^{119}\) They often develop in the abdominal wall, mesentery or retroperitoneum after (procto)colectomy (in particular, within 2 to 3 years), and when developing intra-abdominally (including in the retroperitoneum), they can cause bowel obstruction, perforation, abscess formation, ureteral obstruction, etc., often making treatment difficult.

The mortality rate of FAP patients developing desmoid tumors is reported to be 0-14%.\(^{6,83,118,120,121}\)

2. Types of treatment

Desmoid tumors should be treated taking into account their characteristics including: (1) spontaneous decrease of size or size stabilization,\(^{120,122,123}\) and (2) recurrence that has been reported to occur in 10-68% of cases after resection.\(^{117}\)

Pharmacotherapy (including chemotherapy), surgical resection, radiation therapy, etc., have been used for the treatment of desmoid tumors. In FAP patients, desmoid tumors are often adjacent to the intestine, such as those in the mesentry, and radiation therapy is generally not recommended, because it can cause bowel injury and is poorly effective.\(^{124}\)

Treatment with sulindac (300 mg/day), which is one of the NSAIDs, and tamoxifen (40 to 120 mg/day) or toremifene (180 mg/day), which are antiestrogens, could be selected for large and/or rapidly growing intra-abdominal or abdominal-wall desmoid tumors.\(^{28,126}\)

Both sulindac and antiestrogens have been reported to have a limited effect in reducing the tumor size, but they suppress tumor growth.\(^{27,129}\) Recently, the efficacy of a tyrosine kinase inhibitor, imatinib, has also been examined. Desurmont et al.\(^{126}\) reported that imatinib reduced the tumor size or stabilized the tumor size in 36% of treated cases. On the other hand, Chugh et al.\(^{150}\) reported a 1-year progression-free rate of 66% in inoperable desmoid tumor patients treated with imatinib, but reduction of the tumor size occurred in only 3% of the patients. Therefore, at present, the efficacy of imatinib remains to be clearly established.

Regarding cytotoxic chemotherapy, high response rates were reported with a combination regimen of doxorubicin (DOX) plus dacarbazine (DTIC).\(^{131}\) In Japan also, DOX + DTIC therapy has been found to be effective.\(^{125}\) In addition to DOX + DTIC therapy, methotrexate (MTX) plus vinblastine (VBL) has also been reported to be effective.\(^{133}\)

Desurmont et al.\(^{126}\) compared the response rates of intra-abdominal desmoid tumors to various pharmacotherapies. They found that the response rates were 77% to treatment with cytotoxic anticancer drugs, 50% to treatment with sulindac + tamoxifen, 40% to treatment with tamoxifen, 36% to treatment with imatinib, and 28% to treatment with sulindac. Thus, the response rate of intra-abdominal desmoid tumors was the highest to treatment with cytotoxic anticancer drugs, and they concluded that cytotoxic anticancer drugs could be the first-line treatment. However, it has not been clearly established in which type of intra-abdominal desmoid tumors cytotoxic anticancer drugs should be used as the first-line treatment.

Extra-abdominal desmoid tumors have been reported to show high recurrence rates after resection (20-25%), although the incidence of postoperative complications is low. Because recurrence after resection may not only be caused by incomplete resection, but also possibly by new tumor development at the site of incision, excessive peritumoral resection should be avoided.\(^{140}\) Although surgery should be considered for bowel obstruction due to intra-abdominal desmoid tumors, it may not be successful due to the difficulty of resection or the necessity for massive intestinal resection.\(^{129}\) Smith et al.\(^{135}\) reported the absence of any difference in survival between patients treated by complete resection and patients not treated by complete resection, including by-pass cases.

3. Treatment of intra-abdominal desmoid tumors based on the Church classification

A staging system for intra-abdominal desmoid tumors has been developed by reference to the classification of Church et al.\(^{121}\) (Table 5). Although no prospective studies have been conducted, options include follow-up or use of NSAIDs for stage I tumors, surgery and NSAIDs + tamoxifen, if possible, for stage II tumors, NSAIDs + tamoxifen + chemotherapy for stage III tumors, and chemotherapy or by-pass surgery for stage IV tumors (Figure 17). According to one report, mortality was 0 in stage I/II patients and 15% and 44% in stage III and IV patients, respectively. Stent placement is recommended for ureteral obstruction.
Table 5. Staging System for Intra-Abdominal Desmoid Tumors according to Church’s Classification *ref 121*.

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximal size</td>
<td>&lt;10 cm</td>
<td>10-20 cm</td>
<td>&gt;20 cm</td>
<td></td>
</tr>
<tr>
<td>Growth speed</td>
<td>No growth within 6 months</td>
<td>Growth within 6 months</td>
<td>More than 50% increase in</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>maximal diameter within</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 months</td>
<td></td>
</tr>
<tr>
<td>Uretic obstruction</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Bowel obstruction</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Sensation of tumor</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Restriction of daily life</td>
<td>No</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Hospitalization</td>
<td>Unnecessary</td>
<td></td>
<td>Necessary</td>
<td></td>
</tr>
</tbody>
</table>

TAM: tamoxifen
NSAIDs: nonsteroidal anti-inflammatory drugs

Figure 17. Treatment plan according to the staging system for intra-abdominal desmoid tumors.

CQ15: What malignancies other than those of the gastrointestinal tract should careful attention be paid to in FAP patients?

Recommendation category: None

Thyroid cancer, adrenal cancer, hepatoblastoma, brain tumor, etc., are known to develop in FAP patients, and particularly, many cases of thyroid cancer have been reported. The usefulness of screening tests and surveillance for these tumors has not yet been confirmed.

Thyroid cancer is reported to develop in 1-6.1% of FAP patients13,136,137), with papillary carcinoma accounting for most of the cases. Papillary thyroid cancer develops more commonly in females, with a female:male ratio of 44:1138). The relative risk of thyroid cancer in female FAP patients as compared to the general population is reported to be 23 to 16013,138,139). Thyroid cancer in FAP patients often shows a characteristic histology, i.e., the cribriform-morula variant140,141), and diagnosis of FAP is sometimes made during treatment of the thyroid cancer. Because reported incidences of multiple thyroid cancers and bilateral thyroid cancer are as high as 28.6-69%142,144) and 42-67%142,145), respectively, one report has recommended subtotal thyroidectomy140). However, papillary thyroid cancer associated with FAP has a fa-
Adrenal tumors develop in 7.4-13% of FAP patients. The reported relative risk of adrenal tumors in FAP patients as compared to the general population is reported to be 176 to 90%.

It is estimated that 0.42-0.75% of children with FAP develop hepatoblastoma. The peak age at onset is approximately 3 years, and the relative risk in FAP patients as compared to the general population is reported to be 176 to more than 420. Imaging examinations, including abdominal ultrasonography are used for the diagnosis, and 90% of the patients have high levels of α-fetoprotein (AFP). CHRPE is known to be frequently associated with hepatoblastoma, and FAP patients with a family history of hepatoblastoma are known to be at a higher risk. Surgical resection or chemotherapy should be selected for treatment. Patients in whom the tumor is detected early have a favorable prognosis after complete resection, and one report recommends surveillance at the peak age of onset.

CQ16: What are the points that should be kept in mind when providing genetic counseling to FAP patients/their families?

Recommendation category: B

It is necessary to provide information about FAP and psychosocial support while providing genetic counseling for FAP patients and their families (relatives), including at-risk individuals.

Genetic counseling should be provided to FAP patients, irrespective of whether genetic testing has been performed or not. Genetic testing should be performed mainly by a physician at a time and in a place where the patient can talk calmly, in accordance with the “Guidelines for Genetic Tests and Diagnosis in Medical Practice” of the Japanese Association of Medical Sciences (February 2011), guidelines of the Japanese Society for Familial Tumors, “Ethical Guidelines for Human Genome/Gene Analysis Research,” etc.

In genetic counseling for FAP, comprehensive information about the disease should be provided, including the fact that first-degree relatives of affected individuals have a 50% chance of inheriting the mutation, and that if left untreated, almost a 100% of APC mutation carriers develop colorectal cancer. Furthermore, the significance of genetic testing as one of the options, and its methods, limitations, costs, etc., should be explained, to help the patients and their families make an independent choice about genetic testing. Genetic counseling should be provided not only before and after genetic testing, but also continuously, as necessary.

Genetic or diagnostic testing (colonoscopic examination) of relatives of FAP patients frequently involves minors. When genetic or diagnostic testing is performed in minors, it is desirable to obtain not only the consent of the legal representatives of the subjects, but also informed consent from the subjects themselves after providing them with an explanation according to their level of understanding.

The results of genetic testing of relatives may differ among siblings (mutation carriers and unaffected individuals). Some individuals not carrying the pathogenic mutation have a guilty conscience (survivor guilt), e.g., a feeling that “I alone am safe and I am sorry,” and psychological support for family members not carrying the pathogenic mutation is also sometimes required as part of genetic counseling.

Various tumorous and non-tumorous lesions develop in FAP, necessitating collaboration with multiple departments. It is desirable to provide long-term social, economic, and psychological support as a medical team.
Lynch syndrome include the presence of tumor-infiltrating lymphocytes, a medullary growth pattern, mucinous/signet-ring cell differentiation, and Crohn’s-like lymphocytic reaction \((CQ17, CQ18)\).

A variety of other Lynch syndrome-associated (malignant) tumors can also develop besides colorectal cancer, including endometrial cancer, ovarian cancer \((CQ19)\), gastric cancer, small-bowel cancer, bile duct cancer, pancreatic cancer, renal pelvic/ureteral cancer, brain tumor, and skin tumor \((CQ17)\). Recently, breast cancer, bladder cancer \((CQ20)\), and prostate cancer \((CQ21)\) have also been reported to develop in association with Lynch syndrome.

The risk of development of Lynch syndrome-associated tumors varies depending on the causative gene, the type of mutation, environmental factors, etc. \((CQ16, CQ17)\) (Table 6).

In addition, some individuals carrying the disease-causing genetic mutation remain totally asymptomatic throughout their lives.

**[Major causative genes]**

- Germline mutations in any of the following genes: MLH1 gene on chromosome 3
- MSH2 and MSH6 genes on chromosome 2
- PMS2 gene on chromosome 7

**[Mode of inheritance]**

- Autosomal dominant inheritance

**[Mechanism of malignant transformation]** \((Figure 18)\)

- In Lynch syndrome, a pathogenic germline mutation is present in one allele of one of the mismatch repair genes, and an acquired mutation (or methylation of the promoter region) in the other (wild-type) allele impairs mismatch repair function. As a result, deviations in the number of tandem repeats (microsatellite instability) often occur in the tumors (microsatellites are simple repetitive sequences in the genome.). These genes involved in tumor suppression (such as TGFBR2), cell proliferation, DNA repair (such as MSH3 and MSH6), apoptosis (such as BAX), etc., contain repetitive sequences in the coding regions and mutations tend to develop in these regions.

- The adenoma-carcinoma sequence has been suggested to underlie the development of colorectal cancer in patients with Lynch syndrome, as in cases of sporadic colorectal cancer \((Figure 18)\); however, the precise mechanisms of carcinogenesis in LS-associated colorectal cancer have not yet been fully clarified.

**[Incidence]**

- Lynch syndrome has been estimated to account for 2-4% of all colorectal cancer cases \((CQ19, CQ21)\).
- The incidence in the overall Japanese population is unknown.

**Side Memo 6**

- Changes in the nomenclature of Lynch syndrome

In 1966, Henry T. Lynch et al. \((CQ22)\) reported families in which colorectal cancer and endometrial cancer were more frequently encountered than in the general population. In 1984, Boland et al. \((CQ23)\) classified the conditions into two categories; Lynch syndrome I, characterized by an increased risk of development of only colorectal cancer, and Lynch syndrome II, characterized by increased risk of development of not only colorectal cancer, but also cancer of other organs in the family members. These two conditions have come to be collectively called Lynch syndrome or hereditary non-polyposis colorectal cancer \((HNPPC)\). In 1990, the terms were unified as HNPPC, and in a workshop of the International Collaborative Group on HNPPC \((ICG-HNPPC)\) held in Amsterdam, standardized Amsterdam criteria \((CQ24)\) were proposed to collect HNPPC pedigrees. Causative genes have been reported one after another since 1993. As a result, it had been found that there are many families that carry a causative gene mutation, but do not meet the Amsterdam criteria I, and many others that meet the Amsterdam criteria I, but in which no causative genes can be identified. Therefore, in 1998, the revised Amsterdam criteria \((CQ25)\) \((Table 7)\) were developed taking into consideration the occurrence of malignant tumors other than colorectal cancer, such as endometrial cancer, were proposed, for collaborative research on HNPPC \((CQ26)\). Thereafter, the appropriateness of the term HNPPC was repeatedly discussed, and it came to be thought that the term is inappropriate considering the characteristics of the disease, i.e., the occurrence also of various malignant neoplasms other than colorectal cancer. Currently, the term Lynch syndrome, named after - Dr. Lynch, is commonly used.

- Mismatch repair function

Cells are equipped with the function of detecting and repairing mismatches that occur during DNA replication. Mismatch repair dysfunction increases the frequency of mismatches and insertions/deletions of simple repeat sequences by 10- to 1,000-fold, which results in microsatellite instability \((Side Memo 7: Method for MSI testing and evaluation of the results)\).

- Recent research on the causative genes of Lynch syndrome

1. Germline epimutation

Recently, it was found that epimutations are involved in tumorigenesis in some cases of Lynch syndrome. Epimutations refer to modifications of molecules involved in gene expression, such as aberrant DNA methylation, that can cause changes in gene expression without alterations of the DNA sequence. Although rare, aberrant germline methylation \((hypermethylation)\) of the promoter region of the MLH1 gene is known.
Figure 18. Possible mechanisms underlying colorectal cancer development in patients with Lynch syndrome.

Table 7. Amsterdam Criteria II (ref. 175).

<table>
<thead>
<tr>
<th>At least three relatives must have a Lynch syndrome-associated cancer (colorectal, endometrium, small bowel, ureter, or renal pelvic cancer); all of the following criteria should be met:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• One must be a first-degree relative of the other two;</td>
</tr>
<tr>
<td>• At least two successive generations must be affected;</td>
</tr>
<tr>
<td>• At least one should have been diagnosed before the age 50 years;</td>
</tr>
<tr>
<td>• Familial adenomatous polyposis should be excluded; and</td>
</tr>
<tr>
<td>• Tumor diagnosis should be confirmed by histopathological examination.</td>
</tr>
</tbody>
</table>

gene has been reported as a cause of Lynch syndrome. The EPCAM (TACSTD1) gene is located upstream of the MSH2 gene, adjacent to it, and deletion of its 3’ region (sequences necessary for transcription termination) can cause Lynch syndrome. The deletion allows the EPCAM and MSH2 genes to be continuously transcribed, thereby inducing aberrant methylation of the promoter region of the MSH2 gene and loss of expression of the MSH2 protein. The risk of colorectal cancer development in individuals with EPCAM deletions is comparable to that in patients with Lynch syndrome caused by mutations in the MSH2 gene, although the risk of endometrial cancer development is lower in these individuals. EPCAM deletions have been reported to account for 1-3% of Lynch syndrome cases.

2. Diagnosis

1) Flow of diagnosis

- Definitive diagnosis should be made according to the following Steps 1 to 3 in patients with clinicopathological findings (including family history) suggestive of Lynch syndrome (Figure 19).

Step 1: It should be checked whether the patient meets the Amsterdam criteria II (Table 7, Figure 20A, 20B) or the revised Bethesda guidelines (primary screening).

Step 2: Microsatellite instability (MSI) testing or immunohistochemistry for the causative gene products in the tumor tissue should be performed to confirm high-frequency MSI (MSI-H) or to confirm the absence of mismatch repair proteins (secondary screening) (CQ20, CQ21).

Step 3: Pathogenic germline mutations in the mismatch repair genes should be identified (not covered by the national health insurance program in Japan) for definitive diagnosis. (CQ22, CQ23, CQ24)
Figure 19. Diagnostic process for Lynch syndrome. Microsatellite instability: MSI, high-frequency MSI: MSI-H.

Recently, it was proposed that all patients (or patients aged 70 years or less) with colorectal cancer be screened for Lynch syndrome, irrespective of the clinicopathological findings or family history (Side Memo 7: universal tumor screening).

Note 2: If MSI testing shows MSI-H or immunohistochemistry shows loss of MLH1 expression, the tumor tissue should be tested for the \textit{BRAF} V600E mutation. If the tumor is positive for this mutation, Lynch syndrome can almost certainly be ruled out. Thus, this allows patients who do not have to proceed to Step 3 to be selected. \textit{BRAF} V600E mutation testing is also not covered by national health insurance in Japan, but can be outsourced to testing companies. It must be noted that the \textit{BRAF} V600E mutation has been reportedly found in some colorectal cancers associated with Lynch syndrome caused by mutations in the \textit{PMS2} gene\textsuperscript{180}.

\textit{Step 1. Criteria for primary screening (Table 7, 8)}

- It has been reported that 27-41\%\textsuperscript{172,181} of Lynch syndrome families meet the Amsterdam criteria II\textsuperscript{175} and that 68-89\% meet the revised Bethesda guidelines\textsuperscript{179}, thus, more patients with Lynch syndrome can be identified using the revised Bethesda guidelines\textsuperscript{181}.

- Approximately one-fourth of all colorectal cancer patients fulfill the revised Bethesda guidelines\textsuperscript{182}. Namely, a considerable proportion of non-Lynch syndrome patients with sporadic colorectal cancer also meet the revised Bethesda guidelines\textsuperscript{179}.

- In the JSCCR project studies, 1.2\% of all colorectal cancer patients were found to meet the Amsterdam criteria II\textsuperscript{183}.

\textit{Step 2. Tests used for secondary screening}

- \textbf{MSI testing:}
  - In some tumor cells with impaired mismatch repair function, the number of repeats in microsatellites, which are repetitive sequences of one to several nucleotides in the genome, is different from that in normal cells. This phenomenon is called microsatellite instability (MSI). MSI-H (high-frequency MSI) is usually seen in the tumor tissues in Lynch syndrome. Thus, screening and auxiliary diagnosis of Lynch syndrome has been performed using this phenomenon. This testing is covered by national health insurance (CQ20, Side Memo 8: Method for MSI testing and evaluation of the results).

- In cases with clinical findings suggestive of Lynch syndrome where the results of MSI testing of the colorectal tumor (colorectal adenomas can also be examined, although the detection sensitivity is lower) show MSI-H, Lynch syndrome should be strongly suspected.
In MSI testing, the microsatellite length is compared between normal and tumor tissues, usually using 5 markers (Bethesda markers) (Figure 21). If there are differences in the microsatellite length in the tumor tissue, the tumor tissue is judged as showing MSI. MSI detected with 2 or more markers is defined as MSI-H, MSI detected with a single marker is defined as low-frequency MSI (MSI-L), and MSI detected with none of the 5 markers is defined as

Figure 20. Family tree fulfilling Amsterdam criteria II. (See appendix: Principles in drawing and reading pedigrees)  A: Multiple family members with colorectal cancer  B: Multiple members with Lynch syndrome-associated extra-colonic cancers.
Tumors from patients with colorectal cancer (CRC) should be tested for MSI in the following situations:
1. CRC diagnosed in a patient less than 50 years old.
2. Presence of synchronous, metachronous colorectal, or other Lynch syndrome (LS)-associated tumors, regardless of the age.
3. CRC with MSI-H histology diagnosed in a patient less than 60 years old.
4. CRC diagnosed in a patient with one or more first-degree relatives with a LS-associated tumor, with one of the cancers being diagnosed under the age of 50 years.
5. CRC diagnosed in two or more first- or second-degree relatives with LS-associated tumors, regardless of the age.


Tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.


<table>
<thead>
<tr>
<th>Step</th>
<th>Tests for definitive diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Genetic testing for mutation in the mismatch repair genes:</td>
</tr>
<tr>
<td>2.</td>
<td>The patients’ blood is used to directly determine the presence or absence of pathogenic germline mutations in the mismatch repair genes. If a pathogenic mutation is identified, the patient is definitively diagnosed as having Lynch syndrome. In Japan, this testing is not covered by the national health insurance program, and it is currently performed at the patient’s expense or as research (genetic testing can be outsourced to testing companies). Genetic counseling must be provided before and after the testing. (CQ22, CQ23, CQ24)</td>
</tr>
<tr>
<td>3.</td>
<td>Even if genetic testing for mutations of the mismatch repair genes is considered unnecessary in the screening process, or genetic testing does not reveal any pathogenic mutations in the causative genes, the patient may still have Lynch syndrome.</td>
</tr>
<tr>
<td>4.</td>
<td>For families with clinical features strongly suggestive of Lynch syndrome, genetic testing for mutations in the mismatch repair genes is sometimes performed directly without screening by MSI testing or immunohistochemistry.</td>
</tr>
<tr>
<td>5.</td>
<td>It is desirable to perform genetic testing for mutations in the mismatch repair genes in individuals whose family members show clinical features suggestive of Lynch syndrome (multiple cancers, including colorectal cancer, endometrial cancer, early-onset cancer, etc.)</td>
</tr>
</tbody>
</table>

**Figure 21.** An example of MSI analysis using the Bethesda markers.
3. Treatment

1) Treatment of colorectal cancer

- The following options exist for the extent of resection of the colorectum (types of surgical procedures) in Lynch syndrome:
  (1) Extent of resection equivalent to that adopted for sporadic colorectal cancer
  (2) Total colectomy
  (3) Total proctocolectomy

- No consensus has been reached on the usefulness of prophylactic colectomy, and it is not generally recommended.

- Because colorectal cancer tends to develop at multiple sites of the colorectum in Lynch syndrome, including synchronous or metachronous development, the entire colorectum should be examined before surgery.

- Some reports from Western countries have recommended extended operations, such as total colectomy for colonic cancer and total proctocolectomy for rectal cancer, for colorectal cancer in Lynch syndrome. However, no prospective studies on their usefulness have been conducted, and no consensus has been reached yet. (CQ25)

- Prophylactic colectomy for Lynch syndrome mutation carriers is not generally recommended, because its efficacy has not been assessed. (CQ25)

- Colorectal cancers in most cases of Lynch syndrome show MSI-H. Although 5-fluorouracil (FU)-based anticancer drugs have been reported to be generally ineffective in colorectal cancers showing MSI-H, the usefulness of chemotherapy specifically in Lynch syndrome-associated colorectal cancer has not yet been clarified. (CQ26)

2) Management of extracolonic tumors

- Gastrointestinal tumors (gastric cancer, small-bowel cancer, bile duct cancer, pancreatic cancer, etc.)
- Gynecologic tumors (endometrial cancer, ovarian cancer, etc.) (CQ19)
- Urological tumors (renal pelvic/ureteral cancer, etc.)
- Other tumors (brain tumor, skin tumor, etc.)

- There is no clear evidence of any special considerations required for the above-mentioned tumors (1) to (4), except for the case of gynecologic cancers, in patients with Lynch syndrome. At present, treatment like that for the corresponding sporadic cancers (tumors) is used.

- In Lynch syndrome patients with colorectal cancer, it is desirable to conduct screening for other Lynch syndrome-associated tumors (in particular, gynecologic cancers, urological cancers, and gastrointestinal cancers) prior to elective colectomy.
Table 9. Recommended Surveillance Protocols for Common Lynch Syndrome-Associated Tumors.

<table>
<thead>
<tr>
<th>Sites</th>
<th>Examinations</th>
<th>Lower age limit (years) for starting surveillance</th>
<th>Surveillance interval (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectum</td>
<td>Colonoscopy</td>
<td>20-25</td>
<td>1-2</td>
</tr>
<tr>
<td></td>
<td>Transvaginal ultrasound</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterus, ovary</td>
<td>Endometrial biopsy</td>
<td>30-35</td>
<td>0.5-1</td>
</tr>
<tr>
<td></td>
<td>Endometrial cytology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serum CA125 measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach, duodenum</td>
<td>Gastroduodenoscopy</td>
<td>30-35</td>
<td>1-2</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>Urinalysis and urinary cytology</td>
<td>30-35</td>
<td>1-2</td>
</tr>
</tbody>
</table>

Modifications with ref. 196

4. Postoperative surveillance

1) Surveillance for multiple colorectal cancers and resection of adenomas

- Attention should be paid to the possible development of synchronous cancer in the remaining colorectum after surgery for colorectal cancer in patients with Lynch syndrome, and lifelong regular colonoscopic examination is required. (CQ29)
- Surveillance for recurrence of colorectal cancer after resection should be in accordance with the protocol used for cases of sporadic colorectal cancer.
- Colorectal adenomas, if detected, should be resected, because they may develop into colorectal cancer.

2) Surveillance for Lynch syndrome-associated extracolonic tumors

- A specialist group in Europe proposed the following method of surveillance for the main Lynch syndrome-associated tumors (Table 9)196.
- It was proposed that surveillance be conducted by upper gastrointestinal endoscopy every 1 to 2 years in areas where gastric cancer is common, such as East Asia, and in Lynch syndrome patients with a family history of gastric cancer and their relatives197.
- No consensus has been reached on the method or interval of regular surveillance for endometrial and ovarian cancers. (CQ19)
- Lynch syndrome-associated urological tumors include renal pelvic/ureteral cancer. This type of cancer has been reported to be common in patients with germline mutations in the MSH2 gene, but none of the surveillance methods, including regular urinalysis and urinary cytology, have been demonstrated to be useful in improving prognosis.

5. Surveillance of colorectal cancer patients without a genetic diagnosis of Lynch syndrome

- In patients who are suspected to have Lynch syndrome but have not been diagnosed yet by genetic testing, the possibility of Lynch syndrome should be individually evaluated based on clinical information and the results of MSI testing, which is covered by national health insurance in Japan, and surveillance for Lynch syndrome-associated tumors should be conducted (Figure 22).
- In cases where the patient “meets the Amsterdam criteria II” or “has a past or family history highly suggestive of Lynch syndrome,” in addition to the results of MSI testing showing MSI-H, the patient should be regarded as having Lynch syndrome and surveillance should be conducted even if no genetic testing has been performed.
- In cases where the patient “meets the Amsterdam criteria II” or “has a past or family history highly suggestive of Lynch syndrome,” but the results of MSI testing show MSS or MSI-L (there are no findings strongly suggestive of mismatch repair gene deficiency), Lynch syndrome can certainly not be ruled out (Side Memo 8: MSI testing method and evaluation of the results). In these cases, follow-up should be subsequently performed while paying attention to the personal and family history, with colonoscopic examination for colorectal cancer conducted at least every 3 to 5 years.

- In case the patient “meets the revised Bethesda guidelines, but not the Amsterdam criteria II, or does not have a personal or family history strongly suggestive of Lynch syndrome,” if the results of MSI testing show MSI-H, the patient may have Lynch syndrome (many patients are likely to have sporadic colorectal cancer). Follow-up should be performed while validating the past and family history.
- In MSS or MSI-L colorectal cancer patients who are unlikely to have Lynch syndrome based on the family and medical history, surveillance for Lynch syndrome-associated tumors is not conducted. When patients have symptoms of colorectal cancer, or Lynch syndrome-associated tumors are observed in the patients or their relatives, detailed examination and reevaluation for Lynch syndrome is recommended.
6. Genetic counseling and management of families (relatives)

- It is desirable to provide genetic counseling not only to the patients, but also to their relatives.
- After providing an adequate explanation about the disease to first-degree relatives (parents, children, and siblings) and obtaining their consent, surveillance for Lynch syndrome-associated tumors should be conducted according to the assessed risk.
- For genetic testing, the “Guidelines for Genetic Tests and Diagnosis in Medical Practice” of the Japanese Association of Medical Sciences, guidelines of the Japanese Society for Familial Tumors, “Ethical Guidelines for Human Genome/Gene Analysis Research,” etc., should be observed. In addition, records should be carefully stored, in consideration of the privacy of the subjects.
- In genetic counseling, information about the disease should be provided and the significance of genetic testing as one of the options and its methods, limitations, costs, etc., should be explained to help patients and their families make an independent choice about whether to undergo genetic testing or not. For patients who wish to undergo genetic testing, testing should be performed after obtaining informed consent from the patient. Genetic counseling should be provided not only before and after genetic testing, but also repeatedly, where necessary.
- In principle, because Lynch syndrome-associated tumors generally develop in adulthood, genetic testing should be performed in adulthood.
- It should be ascertained as to whether the patients (clients) want to be apprised of the results of genetic testing with their family members or not. If a patient does not wish to be informed about the results in the presence of family members, an opportunity should be provided for giving the information individually.

1) Management of patient families (relatives) who have been diagnosed by genetic testing to have Lynch syndrome (Figure 23)

- Relatives who are definite mutation carriers or who have not undergone genetic testing should be regarded as having Lynch syndrome and undergo surveillance for Lynch syndrome-associated tumors (Figure 23).
- Relatives who have been confirmed to have no pathogenic mutation should undergo general cancer screening (Figure 23). Information on the necessity of surveillance and significance of genetic diagnosis should be provided to relatives who have reached the age of surveillance for Lynch syndrome-associated tumors. Everyone should decide, of his/her own free will, whether he/she wishes to undergo genetic testing or not through genetic counseling.

2) Management of patient families (relatives) who are suspected to have Lynch syndrome, but for whom no definitive diagnosis has been made

- In relatives of patients who have not undergone genetic testing or in whom genetic testing has failed to yield a definitive diagnosis of Lynch syndrome, individual risk assessment should be carried out by reference to the age of onset,
incidence, etc., of Lynch syndrome-associated tumors in family members, and surveillance for associated tumors should be conducted.

In relatives of patients suspected as having Lynch syndrome, surveillance should be conducted according to the protocol shown in Table 9, or colonoscopy should be started at an age 5-15 years younger than that of the earliest age at diagnosis of colorectal cancer in the family.

Clinical Questions

CQ17: Do Lynch syndrome-associated tumors require different treatments according to the causative gene of Lynch syndrome?

Recommendation category: C

The risk of developing Lynch syndrome-associated tumors may vary greatly depending on the causative gene. Therefore, it has been proposed that surveillance be conducted according to the organ-specific cancer risk, which is related to the causative gene.

Many studies comparing the major causative genes MLH1 and MSH2 have reported that the risk of colorectal cancer is equivalent between patients with MLH1 mutations and those with MSH2 mutations, and that the risk of development of Lynch syndrome-associated tumors (in particular, those of the urinary system) is higher in patients with MSH2 mutations. The risk of colorectal cancer development is lower in patients with MSH6 mutations than in those with MLH1 or MSH2 mutations, but the risk of endometrial cancer development in patients with MSH6 mutations is equivalent to or higher than that in those with MLH1 or MSH2 mutations (Table 10). Therefore, it is desirable to bear in mind, while conducting surveillance, that the incidence of Lynch syndrome-associated tumors varies greatly depending on the causative gene in Lynch syndrome. However, the risk of development of Lynch syndrome-associated tumors for each causative gene has not yet been fully assessed in Japanese.

CQ18: What are the important histologic findings that need to be screened for in cases of colorectal cancer associated with Lynch syndrome?

Recommendation category: C

Tumor-infiltrating lymphocytes, a medullary growth pattern, mucinous/signet-ring differentiation and Crohn’s-like lymphocytic reaction are useful in screening not only for sporadic MSI-H colorectal cancer, but also for Lynch syndrome.

Several histological features are significantly more common in MSI-H colorectal cancers than in non-MSI-H (MSI-L or MSS) colorectal cancers, and these findings are useful to screen for patients with suspected Lynch syndrome. Four histologic findings, namely, (1) tumor-infiltrating lymphocytes (TIL), (2) a medullary growth pattern, (3) mucinous/signet-ring differentiation, and (4) Crohn’s-like lymphocytic reaction, are listed in the revised Bethesda guidelines. However, these histological features are not necessarily specific to Lynch syndrome; they are commonly seen in both Lynch syndrome-associated and sporadic MSI-H colorectal cancers.
**CQ19: How should gynecologic cancers be treated in patients with Lynch syndrome (including mutation carriers who have not developed colorectal cancer)?**

Recommendation category: C

No surveillance method for endometrial and ovarian cancers in patients with Lynch syndrome has been established. Some experts have proposed that transvaginal ultrasonography must be performed in addition to endometrial cytology or endometrial biopsy as part of surveillance for endometrial cancer.

The Lynch syndrome-associated gynecologic cancers are endometrial cancer and ovarian cancer.

Endometrial cancer is the second most common cancer after colorectal cancer in Lynch syndrome and it is regarded as a “sentinel cancer.” Dysfunctional uterine bleeding is the most common subjective symptom. Surveillance methods include endometrial cytology, endometrial biopsy and transvaginal ultrasonography, and definitive diagnosis is made by histopathological examination. Note that routine Pap smear is performed to screen for cervical cancer, but not for endometrial or ovarian cancer.

At present, risk-reducing surgery is the most effective method for the primary prevention of ovarian cancer. If risk-reducing surgery is not selected, surveillance should be conducted, but its usefulness has not been established. Transvaginal ultrasonography and CA125 testing have not been shown to be sufficiently sensitive or specific for hereditary breast and ovarian cancer syndrome, which is characterized by an increased risk of development of ovarian cancer, like in Lynch syndrome. Transvaginal ultrasonography and CA125 testing approximately every 6 months are the secondary prophylaxis in clinical practice. However, there is a risk of so-called interval cancer, in which cancer is detected by the appearance of subjective symptoms before the scheduled medical examination, although the previous medical examination was negative for cancer.

Risk-reducing surgery with hysterectomy and bilateral salpingo-oophorectomy can be considered as options for primary prevention of gynecologic cancer in Lynch syndrome patients who have completed childbearing or who are postmenopausal. In addition, the option of simultaneous hysterectomy and bilateral salpingo-oophorectomy with surgery for colorectal cancer should also be considered for patients with colorectal cancer. Risk-reducing surgery should be performed after obtaining approval from the local ethics committee and carefully considering the medical care system in advance.

The surveillance methods shown in Table 9 ((4) Postoperative surveillance) should be followed in patients who do not wish to undergo risk-reducing surgery and choose to undergo surveillance instead.
CQ20: What are the points that should be kept in mind while conducting screening tests (MSI testing and immunohistochemistry) for Lynch syndrome?

Recommendation category: None

Sensitivity and specificity are equivalent between MSI testing and immunohistochemistry, and immunohistochemistry helps identify the putative causative genes. The costs and convenience of performance of the tests vary from institution to institution, and comprehensive consideration should be given to selection of one of the tests.

It has been reported that more than 90% of colorectal cancers in patients with Lynch syndrome show MSI-H. On the other hand, according to reports from Western countries and Japan, MSI-H colorectal cancer accounts for 12-16% and 6-7% of all colorectal cancers, respectively. Therefore, MSI testing is a useful screening test to shortlist patients with suspected Lynch syndrome. MSI testing has been covered by the national health insurance program since 2006 in Japan as a genetic test for malignancies. When MSI testing is performed, the possibility of hereditary cancer should be fully explained to the individuals and informed consent should be obtained. Related webpages are linked to the website of the Japanese Society for Familial Tumors (http://jsft.umin.jp/).

Clinicians must be aware that some Lynch syndrome patients with germline mutations in the MSH6 gene do not show MSI-H. Therefore, if the patient shows MSI-L or MSS, but meets the Amsterdam criteria II or if the patient has clinical features (early-onset cancer or multiple cancers) strongly suggestive of Lynch syndrome, genetic testing of mismatch repair genes should be considered. MSI testing mainly using mononucleotide repeat markers, which have recently been increasingly used, has also been reported to be highly sensitive in patients with MSH6 mutations (Side Memo 8: Method for MSI testing and evaluation of the results).

On the other hand, immunohistochemistry for mismatch repair proteins has rapidly become popular as a secondary screening test for Lynch syndrome. Immunohistochemistry can be performed at many institutions. In addition, when immunohistochemistry is performed, a thorough explanation should be provided to individuals and informed consent should be obtained, as for MSI testing. Related webpages are linked to the website of the Japanese Society for Familial Tumors (http://jsft.umin.jp/).

MSI testing and immunohistochemistry use different methods, but have equivalent sensitivity and specificity, and immunohistochemistry allows the possible causative gene among 4 MMR genes to be identified. The costs and convenience of performance of these tests vary from institution to institution, and comprehensive consideration, including the examination system at the institution, should be given to the selection of one of the tests. However, if the patient is clinically suspected as having Lynch syndrome even if one test is negative, implementation of the other test allows complementary screening to be performed.

Side Memo 8

Method for MSI testing and evaluation of the results

Clinical testing companies provide MSI testing. Frozen samples or formalin-fixed paraffin-embedded specimens of tumor and non-tumor normal tissues are required for MSI testing (blood samples can be used instead of normal tissues). DNA is extracted from tumor and normal tissues to compare the microsatellite lengths between these tissues. In general, 5 markers (known as the Bethesda markers or NCI panel, consisting of 2 mononucleotide repeat markers and 3 dinucleotide repeat markers) have been used to assess MSI (Step 2. Tests used for secondary screening). Sometimes, when more markers are used, cases in which 30% or more markers show changes in the microsatellite lengths in tumor tissue are defined as having MSI-H. In addition, because mononucleotide repeat markers have high sensitivity, MSI-H is sometimes defined by the presence of instability detected using 3 or more markers. Some MSI tests with mononucleotide repeat markers allow MSI to be assessed using tumor tissue alone, and have rapidly become popular in Japan as well as in other countries.

CQ21: What are the points that must be borne in mind while conducting immunohistochemistry for mismatch repair gene products (proteins)?

Recommendation category: None

From the pattern of loss of the mismatch repair proteins in cell nuclei, genes causing the mismatch repair deficiency can be deduced. When evaluating the staining results, the adequacy of staining should be confirmed using internal positive controls.

1. Internal positive controls

Mismatch repair proteins are localized in the nuclei and are more strongly expressed in proliferating cells. The base of the colonic mucosal glands and germinal centers of lymph follicles are good positive controls in non-tumor tissues (Figure 25). Because tumor tissues generally have high proliferative activity, confirmation of staining of internal positive controls often makes evaluation easier.

2. Staining patterns and evaluation

In tumors without mismatch repair deficiency, all 4 proteins are expressed. In tumors with mismatch repair deficiency, protein expression is lost reflecting the deficiency of mismatch repair genes, but individual mismatch repair gene deficiency does not correspond 1:1 to loss of protein expression (Table 11, Figure 26). Most cases exhibit one of the staining patterns shown in Table 11. If a staining pattern different from any of those shown in Table 11 is obtained, the validity of staining should be checked before considering the possibility of an exceptional case. In principle, invasive cancers show diffuse loss of expression.

The expression of PMS2 in addition to MLH1 is lost in...
tumors with \textit{MLH1} mutations, and the expression of MSH6 in addition to MSH2 is lost in tumors with \textit{MSH2} mutations (Table 11). Therefore, the use of only 2 antibodies, anti-PMS2, and anti-MSH6 antibodies, allows the screening of Lynch syndrome to be performed with a sensitivity equivalent to that using 4 antibodies\cite{207}. If the expression of PMS2 or MSH6 is lost, staining for MLH1 or MSH2, respectively, should be added to deduce the mutated gene.

\textbf{Figure 25.} MSH2 expression in normal colon mucosa. Strong staining is seen in the germinal center of a lymphoid follicle and at the bottom of glands.

\textbf{Table 11.} Immunohistochemical Expression Patterns of the Mismatch Repair Proteins Associated with Each Suspected Causative Gene.

\begin{tabular}{lllll}
\hline
 & \textbf{MLH1} & \textbf{MSH2} & \textbf{PMS2} & \textbf{MSH6} \\
\hline
\textbf{Causative genes} & \multirow{4}{*}{
\begin{tabular}{l}
\textbf{MLH1} \quad - \quad + \quad - \quad + \\
\textbf{MSH2} \quad + \quad - \quad + \quad - \\
\textbf{PMS2} \quad + \quad + \quad - \quad + \\
\textbf{MSH6} \quad + \quad + \quad + \quad - \\
\end{tabular}
}& \\
\hline
\end{tabular}

\textbf{Side Memo 9}

\textbf{Expression of abnormal proteins due to missense mutations}

In some cases of missense mutations (Appendix: II. Method for describing genomic variants; 3. Types of changes), non-functional proteins are expressed. This is known to be relatively common in Lynch syndrome patients with \textit{MLH1} mutations, and in most of these cases, only PMS2 expression is lost\cite{207}. However, there are rare cases in which no abnormalities are detected by immunohistochemistry. Even if no abnormalities are detected by immunohistochemistry, if the patient is clinically strongly suspected as having Lynch syndrome, the addition of MSI testing may allow accurate diagnosis.

\textbf{Secondary mutations in mismatch repair genes due to microsatellite instability}

Some mismatch repair genes have repeat sequences, and secondary mutations may occur in these genes. In some patients with \textit{MLH1} gene mutations (loss of MLH1/PMS2), MSH6 expression is lost diffusely or regionally\cite{207}.

- Loss of MSH6 expression due to preoperative chemoradiotherapy

It has been reported that in colorectal cancer patients administered preoperative chemoradiotherapy, the tumor MSH6 expression may be lost even in the absence of abnormality in the \textit{MSH6} gene\cite{208}.

\textbf{CQ22: What is the significance of genetic diagnosis of Lynch syndrome and what are the important points that should be kept in mind?}

Recommendation category: B

Genetic testing of mismatch repair genes is required for a definitive diagnosis of Lynch syndrome. Individuals for genetic testing should be selected carefully, and after genetic counseling is provided, it should be checked with them whether they wish to undergo the testing or not. The results of genetic testing should be evaluated for the genetic diagnosis of individuals’ relatives and medical management of the individuals and their relatives.

Pathogenic germline mutations in mismatch repair genes should be identified to make a definitive diagnosis of Lynch syndrome. Individuals (patients/relatives) for genetic testing should be appropriately selected, and genetic counseling should be provided before and after the genetic testing. Genetic testing sometimes fails to determine whether the individual has Lynch syndrome or not, and the results should be interpreted carefully. Testing for mismatch repair genes is not covered by the national health insurance program, but can be outsourced to testing companies.

\textit{1. Genetic testing of mismatch repair genes}

Genetic counseling should be provided before and after genetic testing, because there are hereditary disease-specific precautions and considerations. In principle, an explanation about the genetic testing should be given by a physician, but the individuals can be referred to institutions with expertise in providing genetic counseling. If the individuals agree to undergo genetic testing, approximately 2 to 3 mL of blood should be collected and sent to the testing company to perform genetic testing. Direct sequencing is generally used for analysis, but if no mutations are identified, multiplex ligation-dependent probe amplification, Southern blotting,
Figure 26. Immunohistochemistry for mismatch repair proteins in the colorectal cancer specimen resected from a Lynch syndrome patient with a germline MLH1 mutation. Loss of MLH1 (A) and PMS2 (C) and retention of MSH2 (B) and MSH6 (D). Stromal cells served as internal positive controls.

etc., should be used, because a part of a gene may be deleted, duplicated, or rearranged.

2. Evaluation of the results of genetic testing

If a gene mutation obviously causing the disease is found, a definitive diagnosis of Lynch syndrome can be made. After disclosing the results of genetic testing, genetic counseling, future surveillance planning and implementation, genetic testing of relatives, etc., should be considered. On the other hand, even if a genetic mutation is found, its causal relationship to the disease is unclear (a variant of uncertain significance [VUS]) in some cases (CQ23). In these cases, subsequent surveillance should be conducted as if no genetic testing had been performed. Even if no mutations are detected by genetic testing, Lynch syndrome cannot be completely ruled out, because there may be gene alterations that are undetectable by current testing methods or unknown causative genes. Risk assessment should be carried out according to the past medical and family history, and surveillance, as appropriate, should be conducted. If genetic testing of the proband reveals no mutation, genetic testing of other relatives is of little significance.

3. Genetic testing of relatives

Detection of a pathogenic gene mutation in the proband makes it possible to check whether his/her relatives have the same mutation. In this case, only the region containing the identified mutation should be tested. Genetic counseling should also be provided before and after genetic testing of the relatives. Detection of a mutation in one of the causative genes should lead to future surveillance planning and implementation. Unless there is a family history of early-onset (teens to 20s) cancer, genetic testing should generally be performed in adulthood. Everyone should decide, of his/her own free will, about whether he/she should undergo genetic testing or not.

The JSCCR multicenter study showed that in addition to colorectal cancer and endometrial cancer, which are common in Western countries, Lynch syndrome-associated tumors such as gastric cancer, ovarian cancer, and bile duct cancer, were the major causes of death in first-degree relatives of Japanese Lynch syndrome patients. In close relatives with definite Lynch syndrome, it is important to conduct surveillance bearing these malignancies in mind.

CQ23: How should Lynch syndrome patients in whom genetic testing shows a variant of uncertain significance (VUS) be managed?

Recommendation category: C

Patients with VUS should be managed as if no genetic testing had been performed (Figure 22). If possible, the presence or absence of the variant should be assessed in relatives to investigate its association with tumor development. The results of genetic testing show a “variant of uncertain significance (VUS)” in some cases. The interpretation of the
Clinical significance of VUS sometimes changes because of database updating, etc. There are programs to predict the influence of variants on the protein function (Sorting Intolerant From Tolerant [SIFT], http://sift.jcvi.org/index.html; Polymorphism Phenotyping version 2 [PolyPhen-2], http://genetics.bwh.harvard.edu/pph2, etc.). In cases where the presence or absence of the variant in relatives is strongly associated with tumorigenesis and in cases where the pattern of loss of mismatch repair proteins as assessed by immunohistochemistry is consistent with the VUS, the variant is most likely a pathogenic mutation, but further examination is required to confirm this.

If no definite information is available, the patient should be managed as follows.

- If a patient who has an MSI-H tumor or in whom immunohistochemistry shows loss of expression of one of the mismatch repair proteins has the clinical features of Lynch syndrome, he/she should be managed under the assumption that he/she has Lynch syndrome.
- If a patient who has an MSI-H tumor or in whom immunohistochemistry shows loss of expression of one of the mismatch repair proteins has no clinical findings suggestive of Lynch syndrome, periodic follow-up should be continued based on the family/past medical history.

CQ24: What are the points that should be considered while providing genetic counseling to patients with Lynch syndrome and their families?

Recommendation category: B

When genetic counseling is provided to patients with suspected Lynch syndrome and their families (relatives), the explanation provided about the disease should include an outline of Lynch syndrome, the mode of inheritance, the tests required for diagnosis, the risk of development of Lynch syndrome-associated tumors, including colorectal cancer, surveillance, etc., information resources on the disease, psychosocial support, etc.

It is important to keep in mind the following points (1) to (4) while providing genetic counseling to patients/their families for Lynch syndrome:

(1) The medical and family histories of the individuals should be taken.

(2) The following information should be provided.

An outline of Lynch syndrome (clinical symptoms, penetrance, natural course, incidence, causative genes, diagnosis, treatment, prophylaxis, etc.), its mode of inheritance (autosomal dominant inheritance), the risk of development of various cancers in the individuals (and their relatives) with or without a pathogenic mutation, the possibility of detecting gene mutations, the risk of various cancers when there is a pathogenic mutation, an outline of tests for Lynch syndrome (MSI testing, immunohistochemistry, genetic testing for mismatch repair genes, etc.), preventive measures (in particular, surveillance) based on the risk, information resources such as websites and books, information on patient groups, and current state of research in Japan and overseas.

(3) The surveillance protocols for Lynch syndrome-associated tumors according to the risk should be presented.

(4) Psychosocial support should be provided (patients should be asked to give voice to their concerns and anxieties about the disease, conflicts among family members, etc., and should receive empathy from the physician).

CQ25: Which are the surgical procedures that should be selected for colorectal cancer in patients with Lynch syndrome?

Recommendation category: C

No consensus has been reached on whether the same surgical procedures as those for sporadic colorectal cancer should be selected, or extended operations should be adopted, considering the risk of multiple colorectal cancers in patients with Lynch syndrome.

A retrospective cohort study of colorectal cancer in Lynch syndrome reported that the 10-, 20- and 30-year cumulative incidences of development of metachronous colorectal cancer after partial colectomy (segmental resection) were 16%, 41%, and 62%, respectively, and that the risk of development of metachronous colorectal cancer was lower when a longer segment of the intestine was resected.

In addition, according to another retrospective cohort study, approximately 15% of primary colorectal cancers in patients with Lynch syndrome were rectal cancers, and most metachronous colorectal cancers were right colon cancers in patients who underwent proctectomy. Furthermore, endoscopic surveillance at mean intervals of 14 months revealed 10-, 20-, and 30-year cumulative incidences of development of metachronous colorectal cancers of 19%, 47%, and 69%, respectively. There are insufficient data on whether total proctocolectomy should be selected or not for primary rectal cancer.

Also, no consensus has been reached on whether prophylactic colectomy should be performed in mutation carriers who have been genetically diagnosed as having a pathogenic mutation in one of the mismatch repair genes, but have not developed colorectal cancer. The lifetime risk of colorectal cancer development in male patients with Lynch syndrome is 54-74%, and that in female patients with Lynch syndrome is 30-52% (Table 6). Furthermore, a substantial number of mutation carriers do not develop colorectal cancer throughout their lifetimes. Therefore, prophylactic colectomy cannot be uniformly recommended, as in the case of patients with FAP. Accordingly, it is desirable to allow mutation carriers to decide for themselves the course of treatment they would wish to receive, after they are provided an explanation about the risk of development of metachronous colorectal cancer in Lynch syndrome, the necessity and limitations of surveil-
lance, the significance of prophylactic surgery, the postoperative QOL, etc.

CQ26-1: Which are the adjuvant chemotherapy regimens effective for colorectal cancer in patients with Lynch syndrome?

Recommendation category: C

There is no clear evidence of the efficacy of postoperative adjuvant chemotherapy specifically for colorectal cancer in patients with Lynch syndrome. Stage III colonic cancer (colorectal cancer) in Lynch syndrome could be an indication for postoperative adjuvant chemotherapy.

Because there is little evidence of chemotherapy specific to colorectal cancer in patients with Lynch syndrome, chemotherapy is often considered in accordance with that for sporadic MSI-H colorectal cancers. However, it has been reported that postoperative 5-fluorouracil (FU)-based adjuvant chemotherapy is not useful in patients with sporadic MSI-H colorectal cancer, but is useful in MSI-H colorectal cancer patients aged less than 50 years with suspected Lynch syndrome, suggesting that colorectal cancer in Lynch syndrome should be considered differently from sporadic MSI-H colorectal cancers. There are almost no useful data on postoperative adjuvant chemotherapy for sporadic MSI-H rectal cancer or Lynch syndrome-associated rectal cancer.

A meta-analysis of the MSI status and efficacy of postoperative adjuvant chemotherapy including 5-FU in cases with stage II/III sporadic colorectal cancer showed that MSI-H colorectal cancer had a better prognosis than MSS colorectal cancer, but that postoperative adjuvant chemotherapy did not improve the survival or recurrence-free survival in patients with MSI-H colorectal cancer. However, the National Surgical Adjuvant Breast and Bowel Project (NSABP)-C07 trial and the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial showed that oxaliplatin had an additive effect in postoperative adjuvant therapy for both MSI-H and MSS colonic cancers. Therefore, at present, it is not recommended to determine whether stage III colonic cancer is an indication for postoperative adjuvant chemotherapy according to the MSI status. The usefulness of postoperative adjuvant chemotherapy has not been established for stage II colorectal cancer, and it is thought to be less useful, particularly in MSI-H cancers, because these cancers have favorable prognoses.

CQ26-2: What are the chemotherapy regimens effective against metastatic colorectal cancer in Lynch syndrome?

Recommendation category: C

There is no clear evidence of the efficacy of chemotherapy exclusively against metastatic colorectal cancer in Lynch syndrome. The same management strategies as those for sporadic colorectal cancer should be selected.

CQ27: Are there any lifestyle remedies that are effective in preventing carcinogenesis in Lynch syndrome?

Recommendation category: B

Smoking cessation and proper body fat control are recommended to prevent colorectal carcinogenesis in Lynch syndrome. The effects of smoking, body mass index, alcohol consumption, diets (red meat, processed meat, vegetables, fruits, fish, dairy products, and dietary fiber), etc., have been investigated. Studies, including a prospective cohort study, have shown an association of smoking and body mass index with the risk of carcinogenesis. The results of the JSCCR multicenter study suggested that smoking is a risk factor for the development of synchronous/metachronous multiple colorectal cancers in Lynch syndrome.

Based on current evidence, smoking cessation and proper body fat control are recommended to prevent colorectal carcinogenesis in patients with Lynch syndrome.

CQ28: Is there any chemoprophylaxis that is effective in preventing carcinogenesis in Lynch syndrome?

Recommendation category: C

Aspirin may prevent the development of Lynch syndrome-
Cancer in Lynch syndrome and ibuprofen in preventing colorectal cancer. Although retrospective, showed the efficacy of aspirin as compared to Europeans and Americans. On the other hand, a study conducted on a large patient cohort, although retrospective, showed the efficacy of aspirin and ibuprofen in preventing the development of colorectal cancer in Lynch syndrome\(^229\). It remains to be investigated in the future as to what dose and for what duration aspirin should be administered for obtaining this effect. Several studies have reported that low-dose aspirin may prevent the development of sporadic colorectal cancer\(^230\), and a clinical trial of low-dose aspirin in Lynch syndrome patients is ongoing.

**CQ29: Is surveillance by colonoscopy effective in patients with Lynch syndrome?**

Recommendation category: B

Endoscopic surveillance and resection of adenomas reduce the development of and death from colorectal cancer in cases of Lynch syndrome. Patients with Lynch syndrome have been shown to be at a high risk of developing colorectal cancer, including those with remaining large intestine after surgery for colorectal cancer, and regular and lifelong endoscopic surveillance with the aim of any resecting precancerous adenomas and early detection of colorectal cancer is required\(^229,226\). Many studies have recommended that surveillance be started at the age of 20-25 years\(^196\). Regarding the intervals at which the examinations should be conducted, a prospective study by Järvinen et al.\(^227\) reported that endoscopic surveillance at 3-year intervals decreased the mortality from colorectal cancer by 65%. However, observational studies have confirmed the development of advanced cancer over 3-year periods in endoscopic surveillance, and several studies recommend annual surveillance\(^225,228\).

In Lynch syndrome patients, colorectal adenomas often develop at a young age (less than 40 years)\(^228,231\), show MSI-H, show high-grade atypia even if smaller than ordinary adenomas, and undergo malignant transformation within a short period of time\(^222,233\). In addition, the cumulative number of colorectal adenomas developing over a lifetime has been reported to be up to approximately 20\(^234\). Therefore, tumorous lesions, if detected, should be actively resected endoscopically, irrespective of their size.

**Appendix**

I. Principles in drawing and reading pedigrees

1. Points that must be kept in mind while taking the family history (Appendix Figure 1)
   - Information on at least 3 generations should be obtained.
   - It should be checked whether there are any consanguineous marriages (such as cousin marriages).
   - Not only the number of affected individuals, but also the number of unaffected individuals among siblings should be checked.
   - Date of taking family history, name of the person providing the information, and name of the person taking the family history should be described in the pedigree.
   - Maternal and paternal pedigrees should be separately evaluated.

2. Outline of how to draw pedigrees (Appendix Figure 2)
   - The proband (the affected individual leading to the detection of the affected family) should be indicated by P\(\rightarrow\).
   - The client should be indicated by .
   - If possible, the husband (male partner) should be listed to the left of the wife (female partner).
   - Siblings should be listed from left to right in order of birth.
   - The generation number should be indicated in Roman numerals on the left side.
   - Individual numbers should be given in Arabic numerals in order from left to right along generation lines.
   - Necessary clinical information, such as the age at onset (age at diagnosis), affected site (left or right in the case of bilateral disease), course of treatment, surgical procedure, and pathological diagnosis, should be described.
   - Symbols generally used to draw pedigrees are shown below.

   The first-, second-, or third-degree relatives of the proband are shown below.

II. Method for describing genomic variants

The description method proposed by the Human Genome Variation Society (http://varnomen.hgvs.org/) is generally used to describe genomic changes. Usually, information on reference sequences, their location, and any changes should be given in that order.

1. Symbols for reference sequences
   - Genomic reference sequence: g.
   - Coding DNA reference sequence\(^c\): c.
   - RNA reference sequence: r.
   - Protein reference sequence: p.

\(^c\)Coding DNA sequence is a DNA sequence between the start and stop codons that serves as a template for the synthesis of mRNA, which is translated into protein.
Appendix Figure 1. Symbols for family pedigrees.

Appendix Figure 2. The first-, second-, or third-degree relatives of the proband.

2. Locations of variants

(1) Changes at the genomic DNA level should be indicated by “g.,” and the first nucleotide of the reference genome sequence should be numbered 1.

(2) Changes at the coding DNA level should be indicated by “c.,” and the A of the start codon ATG (translation start point) should be numbered 1 (in Appendix Figure 3, the last nucleotide of exon 1 is the 128th nucleotide from the A of the start codon ATG, and should be indicated as c. 128). Because coding DNA sequences are translated into proteins and contain no introns, when a nucleotide position in an intron is shown, the nucleotide number counted from an adjacent exon should be indicated using “+” or “-”. For example, in Appendix Figure 3, the 15th nucleotide from the start of intron 1 should be indicated as “c. 128 + 15,” and the second nucleotide upstream of the start of exon 2 (c. 129) should be indicated as “c. 129 - 2.”

(3) Changes at the RNA level should be indicated by “r,” in accordance with the method for describing the changes at DNA level.

(4) Changes at the protein level should be indicated by “p.,” and the translation initiation methionine should be numbered 1. Both three-letter and one-letter amino acid codes can be used.
3. Types of changes and their descriptions

(1) Changes at the DNA level should be described as follows. Substitution: >; deletion: del; insertion: ins; deletion-insertion: delins; duplication: dup; inversion: inv; conversion: con.

(2) For changes at the protein level, “>” is not used in the case of substitution, but the original and changed amino acids are shown before and after the amino acid position (number), respectively. Other changes, such as deletion (del), insertion (ins), deletion-insertion (delins), duplication (dup), inversion (inv) and conversion (con) are described in a similar manner to those at the DNA level.

In general, changes are commonly described at the coding DNA (c.) or protein (p.) level.

Specific examples are given below.

Example 1) Missense mutation

● c. 146T > A (p. Val49Glu)

The T nucleotide at the 146th position from the A of the start codon ATG is substituted with an A. This is associated with change of the 49th amino acid from valine (Val) to glutamic acid (Glu).

Example 2) Nonsense mutation

● c. 184C > T (p. Glu62Ter or p. Glu62*)

The C nucleotide at the 184th position is substituted with a T. This is associated with the 62nd codon becoming a stop codon, resulting in a stop of protein biosynthesis.

Example 3) Duplication and its associated frame-shift mutation

● c. 175dupA (p. Ile59Asnfs*20)

The A nucleotide at the 175th position is duplicated and the 176th nucleotide becomes A with the shift in the codon reading frame (this shift of the reading frame is called frame shift and designated as “fs”). This is associated with change of the 59th amino acid from isoleucine (Ile) to asparagine (Asn), and furthermore, with the 20th codon from this site becoming a stop codon (fs*20), resulting in the termination of protein biosynthesis.

Example 4) Deletion and its associated frame-shift mutation

● c. 3927_3931delAAAGA (p. Glu1309Aspfs*4)

The nucleotides the 3927th to 3931th position, AAAGA, are deleted. This is associated with change of the 1309th amino acid from glutamic acid (Glu) to aspartic acid (Asp) and the 4th codon from this site becoming a stop codon (fs*4).

Example 5) A mutation in an intron

● c. 792 + 1G > A

The G nucleotide at the first position following the last exon is substituted with an A. This is speculated to be associated with abnormal splicing.

Example 6) Exon deletion

● c. 458–627 + del

At least one exon (DNA sequence from C. 458 to C. 627) is deleted (unknown nucleotides in the deleted intron region are indicated by “?”).

In addition, to assess whether the variant obtained causes disease or not, registration of the variant in databases such as InSiGHT (http://insight-group.org/variants/database/) and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) should be checked, and a comprehensive assessment based on the results is sometimes required.

It cannot be necessarily said that variants listed in databases cause disease, and careful management is required. Variants are usually classified into 5 categories according to whether they can potentially be associated with disease or not (Attachment Table 1).

Attachment

I. Familial adenomatous polyposis

Familial adenomatous polyposis in Japan: Data from the JSCCR “A retrospective multicenter study of familial adenomatous polyposis” (n = 303) (Attachment Table 1-5)

II. Lynch syndrome

Germline mutations in Lynch syndrome in Japan: Data from the JSCCR “Registration and genetic analysis of HNPCC (secondary study)” (Attachment Table 6)

[Translated from Japanese235) to English with a permission from the publisher of the original version]

Conflicts of Interest

Kei Muro received lecture fees from Chugai, Takeda, and Eli Lilly and research fundings from MSD, Daiichi Sankyo,
**Attachment Table 1.** Number of Colorectal Cancers According to the Phenotype of Familial Adenomatous Polyposis.

<table>
<thead>
<tr>
<th>Number of colorectal cancers</th>
<th>Profuse type</th>
<th>Sparse type</th>
<th>AFAP</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18 (62.1%)</td>
<td>50 (73.5%)</td>
<td>15 (83.3%)</td>
<td>83 (72.2%)</td>
</tr>
<tr>
<td>2</td>
<td>4 (13.8%)</td>
<td>13 (19.1%)</td>
<td>3 (16.7%)</td>
<td>20 (17.4%)</td>
</tr>
<tr>
<td>3</td>
<td>6 (20.7%)</td>
<td>3 (4.4%)</td>
<td>0 (0.0%)</td>
<td>9 (7.8%)</td>
</tr>
<tr>
<td>4</td>
<td>0 (0.0%)</td>
<td>1 (1.5%)</td>
<td>0 (0.0%)</td>
<td>1 (0.9%)</td>
</tr>
<tr>
<td>5</td>
<td>1 (3.4%)</td>
<td>1 (1.5%)</td>
<td>0 (0.0%)</td>
<td>2 (1.7%)</td>
</tr>
</tbody>
</table>

AFAP: attenuated FAP

**Attachment Table 2.** Stage of Colorectal Cancer According to the Phenotype of Familial Adenomatous Polyposis.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Profuse type</th>
<th>Sparse type</th>
<th>AFAP</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>8 (27.6%)</td>
<td>18 (26.9%)</td>
<td>5 (27.8%)</td>
<td>31 (27.2%)</td>
</tr>
<tr>
<td>Stage II</td>
<td>4 (13.8%)</td>
<td>14 (20.9%)</td>
<td>6 (33.3%)</td>
<td>24 (21.1%)</td>
</tr>
<tr>
<td>Stage IIIa</td>
<td>5 (17.2%)</td>
<td>14 (20.9%)</td>
<td>2 (11.1%)</td>
<td>21 (18.4%)</td>
</tr>
<tr>
<td>Stage IIIb</td>
<td>8 (27.6%)</td>
<td>7 (10.4%)</td>
<td>3 (16.7%)</td>
<td>18 (15.8%)</td>
</tr>
<tr>
<td>Stage IV</td>
<td>4 (13.8%)</td>
<td>14 (20.9%)</td>
<td>2 (11.1%)</td>
<td>20 (17.5%)</td>
</tr>
</tbody>
</table>

*: according to the classification proposed by JSSCR

**Attachment Table 3.** Cumulative Incidence of Development of Colorectal Cancer and Duodenal Adenoma.

<table>
<thead>
<tr>
<th>Age (Years)</th>
<th>Colorectal cancer</th>
<th>Duodenal cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Profuse type</td>
<td>Sparse type</td>
</tr>
<tr>
<td>20</td>
<td>0%</td>
<td>1.1%</td>
</tr>
<tr>
<td>30</td>
<td>21.4%</td>
<td>9.6%</td>
</tr>
<tr>
<td>40</td>
<td>47.7%</td>
<td>41.1%</td>
</tr>
<tr>
<td>50</td>
<td>68.3%</td>
<td>54.8%</td>
</tr>
<tr>
<td>60</td>
<td>-</td>
<td>80.2%</td>
</tr>
</tbody>
</table>

**Attachment Table 4.** Cumulative Risk of Development of Desmoid Tumors after Colorectal Resection.

<table>
<thead>
<tr>
<th>Cumulative risk (%)</th>
<th>1y</th>
<th>2y</th>
<th>3y</th>
<th>4y</th>
<th>5y</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.20%</td>
<td>10.20%</td>
<td>11.90%</td>
<td>12.90%</td>
<td>13.40%</td>
<td></td>
</tr>
</tbody>
</table>

**Attachment Table 5.** Postoperative Complications after Restorative Proctocolectomy+Ileal-Pouch Anal Anastomosis.

<table>
<thead>
<tr>
<th></th>
<th>Conventional open surgery</th>
<th>Stapled anastomosis</th>
<th>Hand-sewn anastomosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intestinal obstruction</td>
<td>6.5%</td>
<td>8.1%</td>
<td>5.7%</td>
</tr>
<tr>
<td>Anastomotic leakage</td>
<td>0%</td>
<td>0%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Anastomotic stricture</td>
<td>3.4%</td>
<td>0%</td>
<td>5.7%</td>
</tr>
<tr>
<td>Intra-abdominal abscess</td>
<td>3.5%</td>
<td>0%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Wound infection</td>
<td>2.2%</td>
<td>0%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Dysuria</td>
<td>1.3%</td>
<td>0%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Erectile dysfunction</td>
<td>0%</td>
<td>0%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Ejaculatory dysfunction</td>
<td>12.5%</td>
<td>4.3%</td>
<td>4.7%</td>
</tr>
</tbody>
</table>
### Attachment Table 6. Germline Mutations in Lynch Syndrome in Japan: Data from the JSCCR “Registration and Genetic Analysis of HNPCC (Secondary Study)”

<table>
<thead>
<tr>
<th>Mismatch repair gene</th>
<th>Type of mutation</th>
<th>Regions (Sites) of mutation</th>
<th>Germline nucleotide change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MLH1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Substitution</td>
<td>Intron2, splice acceptor site</td>
<td>c.207+1_c.207+2delGT (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon3</td>
<td>c.209_211delAAAG (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon4</td>
<td>c.319_320delAT (p.I1107Kfs*14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon6</td>
<td>c.472delA (p.N158Fs*2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intron6, splice donor site</td>
<td>c.545+3delAC (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td>Deletion</td>
<td>Exon9</td>
<td>c.846_1848delAAAG (p.K616del)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon1-5</td>
<td>c.9-4968_c.453+696del109180 (exon1-5 deletion)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon5</td>
<td>c.381-431_c.453+717del1221</td>
</tr>
<tr>
<td></td>
<td>Insertion</td>
<td>Exon5</td>
<td>c.440_441insT (p.Y157Lfs*15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12</td>
<td>c.1039_1409+2347del6933ins101 (exon12 deletion)</td>
</tr>
<tr>
<td></td>
<td>Duplication</td>
<td>Exon6</td>
<td>c.464dupT (p.Y157Lfs*15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12-13</td>
<td>c.1039_1409+2347del6933ins101 (exon12-13 duplication)</td>
</tr>
<tr>
<td></td>
<td>Substitution</td>
<td>Intron1, splice acceptor site</td>
<td>c.211+1G&gt;C (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intron5, splice donor site</td>
<td>c.1165C&gt;T (p.R389*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon7</td>
<td>c.1204C&gt;T (p.Q402*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon7</td>
<td>c.1225C&gt;T (p.Q409*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon7</td>
<td>c.1255C&gt;T (p.Q419*)</td>
</tr>
<tr>
<td></td>
<td>Deletion</td>
<td>Exon10, splice donor site</td>
<td>c.1511-1G&gt;A (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12</td>
<td>c.1661+1G&gt;A (aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12</td>
<td>c.1861C&gt;T (p.R621*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12</td>
<td>c.1865C&gt;T (p.P622L)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon12</td>
<td>c.1915C&gt;T (p.H639Y, aberrant splicing)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon14</td>
<td>c.2455A&gt;T (p.K819*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon15</td>
<td>c.2563C&gt;T (p.Q855*)</td>
</tr>
<tr>
<td><strong>MSH2</strong></td>
<td></td>
<td>Exon2</td>
<td>c.274_276delCTT (p.L92del)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon7</td>
<td>c.1226_1227delAG (p.Q409Rfs*7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon11</td>
<td>c.1705_1706delGA (p.E569Rfs*2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon11</td>
<td>c.1744delG (p.V582fs*8)</td>
</tr>
<tr>
<td></td>
<td>Deletion</td>
<td>Exon13</td>
<td>c.2031_2032delAT (p.I679Rfs*19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon14</td>
<td>c.2309delT (p.P770fs*42)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon1</td>
<td>c.1-7550_c211+2019del9780 (exon1 deletion)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon1-6</td>
<td>c.1-19640_c1076+604del2982 (exon1-6 deletion)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon6-7</td>
<td>c.943-956-c1276+12033del26275 (exon6-7 deletion)</td>
</tr>
<tr>
<td></td>
<td>Duplication</td>
<td>Exon14</td>
<td>c.2300_2303delCAGAinsATATATAT (p.S767Yfs*20)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon5-6</td>
<td>c.793-455_c1076+5894dup8510 (exon5-6 duplication)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon7</td>
<td>c.1077-1058-c1276+207dup10991 (exon7 duplication)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon2</td>
<td>Exon2 duplication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon13</td>
<td>Exon13 duplication</td>
</tr>
<tr>
<td><strong>MSH6</strong></td>
<td>Duplication</td>
<td>Exon5</td>
<td>c.3261dupC (p.F1088Lfs*5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exon5</td>
<td>c.3403dupC (p.N1136Lfs*31)</td>
</tr>
</tbody>
</table>
Kyowa Hakko Kirin, Ono, Shionogi, and Gilead Sciences. Takako Nakajima received lecture fees from Taiho Pharm., Chugai Pharm. and also received research funding from Taiho Pharm., Chugai Pharm., Takeda Pharm., MSD, Ono Pharm., AstraZeneca, and Dainippon Sumitomo Pharm. Takayuki Yoshino received a research funding from MSD K.K. and GlaxoSmithKline K.K. Shinji Tanaka received research funding from EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., JIMRO Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., Daiichi Sankyo, Ltd., Sumitomo Bakelite Co., Ltd., Asahi Kasei Medical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Zeria Pharmaceutical Co., Ltd. and also received lecture fees: EA Pharma Co., Ltd., Olympus Co., Ltd. Narikazu Boku received research funds from Taiho Pharmaceutical and Ono Pharmaceutical. Yasuhiro Shimada received research funding from Taiho, Lilly, Merk-Serono, and MSD. Takako Nakajima received lecture fees: EA Pharma Co., Ltd., Olympus Co., Ltd. Narikazu Boku received research funding from Taiho Pharmaceutical and Ono Pharmaceutical. Yasuhiro Shimada received research funding from Taiho, Lilly, Merk-Serono, and MSD. The other authors have no conflicts of interest and funding that should be declared.

Source of Funding

Development of the JSCCR Guidelines 2016 for HCRC was funded by the JSCCR.

References


Clinical guidelines for hereditary colorectal cancer


Clinical guidelines for hereditary colorectal cancer


490-7.


